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ABSTRACT
Introduction:  PCR testing at birth ('birth-testing') is conditionally advised by new World Health Organization 
guidelines for rapid diagnosis of infants infected with HIV in utero. Prompt diagnosis and early introduction of 
antiretroviral therapy (ART) can dramatically reduce mortality in HIV-infected infants. However, a negative 
result at birth must be followed by engagement in subsequent routine early infant diagnosis (EID) services 
(recommended at 6-10 weeks of age) to rule out intra-partum infection. There are few data on the 
implementation of this approach in sub-Saharan Africa and whether birth-testing affects the uptake of 
subsequent routine EID testing is unknown.         
Methods: We conducted a retrospective cohort study using routine clinical and laboratory data from a large 
obstetric hospital in Cape Town. All infants suspected to be at high risk of HIV-transmission, underwent birth-
testing between July 2013-August 2015. Infants with a negative birth-test were matched to HIV-exposed infants 
who did not receive birth-testing. Maternal antenatal and obstetric characteristics of neonates were abstracted 
via folder review. Primary outcome was any subsequent HIV-PCR test before the end of follow-up, ascertained 
from the National Health Laboratory Service database. Data were analyzed using logistic regression models, 
examining independent predictors of presentation at follow-up EID testing. 
Results: Overall, 575 neonates underwent birth-testing, with 22 positive (3.8%) and 551 negative results. At 
follow-up EID presentation (n=871), 4 infected infants were identified (0.4%). Fewer infants who underwent 
birth-testing presented for later EID compared to infants who did not receive a birth-test (73% vs 85%), (Odds 
Ratio, 0.46; 95% confidence interval, 0.34-0.62). Infants who underwent birth-testing, also presented for later 
EID at a significantly older age (mean age 60 days vs.50 days, p<0.001). The significantly lower rate of EID 
presentation among birth-tested children persisted in multivariable analyses adjusting for maternal age, nadir 
CD4 cell count, ART use during pregnancy, gestation, infant sex, birthweight and infant feeding modality 
(Adjusted odds ratio, 0.60 95% confidence interval, 0.40-0.88).  
Conclusions: Neonates undergoing HIV testing at birth may be less likely to present for subsequent EID testing 
than those not birth-tested. Emphasis must be placed on appropriate counseling provided to caregivers on the 
need for further HIV testing after negative birth-test results. 
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PART A: RESEARCH PROTOCOL 
 
STUDY SYNOPSIS 
Protocol for epidemiological study of the impact of introducing an HIV-PCR test at birth for HIV-exposed 
infants in Cape Town. 
 
Study Design: Retrospective cohort study of HIV-exposed infants born at Mowbray 
Maternity Hospital, Cape Town. 
Duration: 9 months to completion: 5 months data collection, 2 months data analysis, 2 
months dissemination of findings.  
Sample Size: Cohort will be assembled retrospectively and include 1102 HIV-exposed 
infants.  
Population: Infants born at Mowbray Maternity Hospital, Cape Town identified as HIV-
exposed by either maternal self-identification with recorded diagnosis on 
their Road to Health Card or confirmed rapid antibody test. 
Primary Study Objective: Describe attendance at routine EID services stratified by receipt of an HIV-
PCR test at birth, and to investigate possible predictors of non-attendance in 
this population. 
Secondary Study Objective: Examine the yield of positive results at each HIV-PCR test and potential 
 linkage to care for infected infants. 
Data collection:  Data will be collected retrospectively from routine medical service records 
of HIV-exposed infants and their HIV-infected mothers. The National 
Health Laboratory Service database will be searched for HIV-PCR results.  
Informed Consent: No direct contact with participants, no informed consent will be 
administered. Multiple steps will be taken to minimize the risk of any loss 
of confidentiality throughout study design and conduction of the research.  





Global HIV/AIDS Epidemic 
According to UNAIDS there are an estimated 37 million people living with Human Immunodeficiency Virus 
(HIV) globally, of whom, 2.6 million are children under 15 years of age (1). HIV infections in infants are 
predominantly the result of mother-to-child-transmission (MTCT), with those infected in utero at highest risk of 
rapid disease progression, and mortality (2,3). Prevention programmes involving the scale-up of treatment for 
pregnant and post-partum women have averted a potential 1.3 million infections among children since 2000 (4). 
Today the majority of HIV-infected women are receiving lifelong antiretroviral therapy (ART) during 
pregnancy, preventing transmission of HIV to both the unborn child, and uninfected partners (4,5). MTCT rates 
have fallen below 1% in Europe and North America, with several low resource settings (Cuba & Thailand) also 
reaching unprecedented lows in 2016 (6,7). However, prevention of mother-to-child transmission (PMTCT) 
coverage is not yet at 100%, and there are significant concerns regarding adherence during pregnancy, meaning 
vertical transmissions continue to occur (5,8,9). In sub-Saharan Africa, an estimated 200,000 infants were 
infected with HIV in 2014, almost 90% of the global total (4). For infants who do acquire the infection 
perinatally, mortality levels are extremely high between the postneonatal period and 6 months of age (10,2). In 
South Africa, 70% of maternal deaths and 50% deaths for children under five years of age were associated with 
HIV (11,12). 
Research from the South African CHER trail demonstrated that prompt diagnosis and early introduction of ART 
can dramatically reduce mortality in children infected with HIV. However, diagnosis of paediatric HIV is a 
complex process, requiring multiple postpartum visits for mother infant dyads. The World Health Organization 
(WHO) recommends that all HIV-exposed infants are tested by 6 weeks of age, and those who return a positive 
result are immediately referred for ART initiation (13). However, there is recognition that loss to follow-up 
(LTFU) during the early infant diagnosis (EID) pathway is a major barrier to linking infected infants to care and 
improving early childhood survival in high burden settings (14).  
Barriers to the EID cascade 
The requirement for virological assays in paediatric HIV diagnosis rather than cheap serological assays, used for 
HIV diagnosis in adults, has presented both cost and acceptability concerns for EID programmes (14,15), but 
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dried blood spot (DBS) specimen collection techniques for nucleic acid amplification tests (NAAT) (or 
polymerase chain reaction (PCR) assays) have been shown to be sensitive and specific for diagnosis of 
paediatric HIV (16,17). DBS removes the need for phlebotomy and cold chain specimen storage permitting 
decentralized testing and expanding access in many high burden countries (18,19).  The South African 6 week 
EID test has been scheduled so as to coincide with early childhood immunization timetables. Vaccination visits 
in South Africa have a coverage of 94%, and by incorporating EID testing into an established programme, 
implementation costs are reduced whilst maximizing access for HIV-exposed infants (10). However, in 2014, 
only half of those in need presented for a virological test. Access to EID does not ensure an infected infant will 
receive their result as LTFU occurs throughout the cascade (4). 
The EID cascade is made up of multiple steps (Figure 1); specimen collection, transport and processing, and 
result return, presenting multiple points at which mother-infant dyads can be lost from care. Attrition between 
delivery and presentation to testing has been widely studied, for example, a recent study from Johannesburg, 
South Africa, found that 20% of HIV-infected infants had died or become lost to follow up by 6 weeks of age 
(20).  Studies from Botswana and Malawi indicate that despite known maternal status many HIV-exposed 
infants attending well child visits do not receive a virological test and therefore never enter the EID pathway 
(21,22). Even after presentation for testing, loss to follow up is known to continue throughout the cascade. 
Research carried out in Tanzania found that only 74% of HIV-PCR results were returned to the clinic and only 
34% returned to the caregiver (23). In high burden rural settings there can be major delays in specimen 
processing. Nuwagaba-Biribonwoha et al in Tanzania and Hassan et al. in Kenya found result return to 
caregivers could take up to 3 months after the initial specimen collection (24,25). It is argued that this waiting 
time results in operational delays to initiating infants on ART and causes anxiety and worry for caregivers (14).  
Research into barriers of retention within PMTCT services have identified not only health system constraints 
but also many individual and socioeconomic factors. As caregivers bear ultimate responsibility for EID 
presentation it is important to consider all possible influences on LTFU within the cascade. Relationships, 
family or community influences could all affect EID presentation (26–29). A recent study from South Africa 
suggests that fear of discrimination is often a cause of dissociation from care (28). Further research is needed in 
this area, but it is clear that novel interventions are required to identify infected infants and link them to care.   
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HIV-PCR Testing at Birth 
In a setting with high coverage of maternal and infant prophylaxis, Lilian et al. demonstrated that by using more 
sensitive HIV assays 76% of all early vertical transmissions were detectable at birth (30). It is reasoned that 
using HIV-PCR testing at birth could overcome many of the logistical delays in the initiation of treatment for 
infected infants. By returning EID results in the post-partum period prior to discharge, LTFU could be reduced 
(31). The availability of on-site laboratories at higher level facilities prevent delays in result return, but primary 
care still encounter many logistical challenges around transportation of samples to central laboratories and PCR 
processing times which delay result return and mean multiple post-partum visits are required for mother infant 
dyads potentially increasing the probability of LTFU (14,24,32,33). Point-of-care (POC) could circumvent 
many of the logistical challenges and allow for result return in a single visit whilst reducing the delay in 
initiating infected infants on ART. Two mathematical models relating to the cost effectiveness and impact of 
birth testing within the EID cascade by Lilian et al. and Franke et al. (pre-publication) have found that adding 
birth testing significantly increases the life years saved in infected infants by reducing mortality of infants in the 
early weeks of life (34,35). 
Paediatric HIV testing in South Africa 2014 
Over the past decade, there has been substantial research around the EID cascade. Focus has been placed on 
reducing the number of infant infections and understanding the scale of LTFU within the cascade. However, 
little headway has been made on increasing the number of infected infants linked to care and the proportion of 
infants currently receiving treatment lags far behind adults (36,37). In consideration of the high mortality rate in 
the neonatal period and high levels of loss to follow up at 6 week testing, the South African National 
Department of Health became the first high burden, resource limited country to implement HIV-PCR testing at 
birth in 2014 (Figure 1). Revised clinical guidelines for the PMTCT of HIV included HIV-PCR testing at birth 
for HIV-exposed infants thought to be at high risk of perinatal transmission (38). Risk criteria include low birth 
weight and prematurity as well as those born to mothers on ART for less than 3 months during pregnancy or 
with a viral load of above 1000 copies per milliliter of blood (14,39). Infants would be required to return for a 
follow up test at 6 weeks of age to detect intra-partum infections, the same requirement as for all HIV-exposed 
infants. However, there is a paucity of data on the diagnosis or treatment of infants during the neonatal period, it 
is therefore unknown what impact the addition of a PCR test at birth will have on the current yield and coverage 
of early infant diagnosis (EID) services. 
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Background to proposed research – barriers to HIV-PCR testing at birth 
As HIV-PCR testing at birth is only a conditional recommendation from the WHO, South Africa is the first high 
burden, resource limited country to implement HIV-PCR testing at birth (15,40). Currently little to no evidence 
is available to guide policy makers on amendments to resource provisions or counseling emphasis. The WHO 
have called for additional information on birth testing as previous research has highlighted the post-partum 
period as a weak link in the continuum of care. Qualitative research studies from South Africa suggest that 
despite a high level of awareness of MTCT, HIV knowledge gaps exist on infant diagnosis and many caregivers 
remain uncertain about six-week EID services and early initiation of ART in HIV-infected infants (28,41). 
Hassan et al report that post-partum care was often inadequately covered during the antenatal period during 
PMTCT services (26–29). The introduction of an additional test for paediatric HIV without changes to 
counseling procedures could cause confusion around the significance of the birth test result and a requirement to 
attend a second test at 6 weeks. In turn, this could negatively impact the loss to follow up for routine EID 
services at 6 weeks. The only previous research conducted on this topic, an observational study from the 
Figure 1 Early infant diagnosis (EID) cascade in South Africa 2015: HIV-exposed non-low risk infants receive a birth test and 
require further follow up if the specimen is negative. They then enter the general EID cascade with all low-risk infants. This process 
includes; specimen collection, transport, and laboratory processing before the relay of results to both healthcare providers and infants’ 
families/caregivers followed by linkage to care.
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Western Cape, found that only 49% of infants returned for follow up testing having previously received a birth 
test, far below the national estimates of EID coverage (42).  
 
Introducing birth testing nationally in South Africa has been a somewhat controversial issue considering the 
shortage of evidence available for initiating ART in the first weeks of life and the unknown impact of adding an 
additional test to the cascade. Birth testing could nonetheless have significant implications for an HIV-exposed 
infant’s health. Infants infected in utero could access treatment earlier, but for those infected intra-partum there 
could be severe consequences if levels of coverage at 6 week testing fall such that infants may miss diagnosis 
and are therefore unable to access ART in an adequate timeframe.  
STATEMENT OF THE PROBLEM  
 
It is apparent from the literature that there is little evidence around HIV-PCR testing at birth. The changes to the 
South African 2014 National Policies on PMTCT make it the first high burden, low resource country to 
implement HIV-PCR testing at birth. The impact of receiving a result within 48hours of life is complex and may 
have many repercussions, both positive and negative. As South Africa moves to a universal policy of testing all 
HIV-exposed infants at birth in 2016, the impact of birth testing needs to be evaluated to provide further 
evidence around the yield of positive results, linkage to care and to consider the possible consequences on 
coverage levels at routine follow-up EID visits.   
 
The proposed study has the potential to make a significant contribution to improvements in EID services in 
South Africa. Birth testing could help to maximize the benefits of antiretroviral therapy for child health and 
could have a considerable effect on the number of children who are successfully linked to care. However, there 
is currently little research around the impact of birth testing on the EID cascade. If levels of loss to follow up are 
significantly different to those who did not receive a birth test, there could be further requirements for research 
on how best to counsel and manage services appropriately, especially for mothers of infants whose birth test is 
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STUDY AIMS & OBJECTIVES 
Study aim  
The overall aim of the proposed research is to investigate attendance at EID testing among HIV-exposed infants 
born at Mowbray Maternity Hospital, comparing mother infant dyads who received an HIV-PCR test at birth, to 
dyads who did not receive an HIV-PCR test at birth.  
 
Objectives 
1. Examine the proportion of infants attending follow-up EID testing who received an additional HIV-PCR 
test at birth compared to those who did not receive a birth test.  
a) To examine the time at which EID testing takes place for each cohort. 
b) To investigate maternal and infant socio-demographic, obstetric, and clinical characteristics as 
possible predictors of EID presentation.   
2. Determine the number and proportion of confirmed positive and negative HIV-PCR tests in relation to the 
number of HIV-exposed neonates:  
a) Within 48 hours of birth (in utero transmission rate)  
b) Follow up testing (intrapartum / early postpartum transmission rate) 
c) Compare the proportion of infants confirmed positive at routine EID testing between high risk 
infants who underwent birth testing and infants who did not receive a HIV-PCR at birth 
3. Examine linkage to care of infected infants 
Hypothesis 
It is hypothesized that presentation at EID testing will be lower in those who received an HIV-PCR test at birth, 
but that due to the targeted HIV-PCR testing at birth, there will be a higher yield of infected infants at this time 
point. 




Study Design  
In order to address these objectives a retrospective descriptive folder review and database search is proposed. 
Infants born to HIV-infected women at a secondary level obstetric hospital who were identified as high risk and 
therefore received an HIV-PCR test at birth are included in a hospital database. Infants born to HIV-infected 
women at the obstetric hospital not identified as high risk, who did not receive a birth test are recorded in 
PMTCT, labour and theatre registers. Infants born between July 2013 and August 2015 will be included, folder 
review for all infants will collect maternal obstetric and infant clinical characteristics. Infant HIV-PCR results 
will be followed until February 2016.  
 
Study Population  
All HIV-exposed infants who were delivered at Mowbray Maternity Hospital (MMH), who received an HIV-
PCR test at birth between July 2013 and August 2015 will be included. A cohort of HIV-exposed infants who 
did not receive an HIV-PCR test at birth will be assembled retrospectively by review of routine data records 
from the hospital (PMTCT, labour and theatre registers). There will be no direct contact with any participants 
for this research.    
 
Inclusion Criteria 
Maternal HIV status for Mowbray Maternity Hospital (study site) is documented from confirmed finger-prick 
rapid test or documentation of HIV status for those women self-reporting HIV diagnosis in the Road to Health 
card. Participants who had no record of delivery at MMH and may have been transferred to the study site after 
delivery will be excluded from the analysis as date of birth cannot be confirmed.    
 
Sample size  
Over 500 infants were delivered at MMH and received an HIV-PCR test at birth over the 2 year study period, a 
control sample of HIV-exposed infants who did not receive a birth test will be taken as a comparison group. 
A cohort of HIV-exposed infants who received a birth test and a cohort of infants who did not receive an HIV-
PCR test at birth should be considered using 80% power (β=0.2) and a two-sided α=0.05. Current estimates of 
coverage of EID before 3 months of age are between 50-80% (43–45). Sample size calculations generates a 
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required sample size of 539 minimum in each group. As 575 infants received a HIV-PCR test at birth, all will be 
included in the study to maximize the accuracy of estimates produced during the analysis. 
 
Estimated sample sizes required under different assumptions 
Proportion of mother infant 
dyads presenting to care in the 
cohort who received birth 
testing 
Absolute increase in 
outcome, control   
minus intervention 
Proportion of mother-infant 
dyads presenting to EID 





0.55 0.1 0.65 61 
0.60 0.05 0.65 234 
0.60 0.08 0.68 90 
0.65 0.05 0.70 219 
0.68 0.02 0.70 1330 
0.70 0.05 0.75 199 
0.70 0.02 0.72 1280 
0.72 0.03 0.75 539 
0.75 0.05 0.80 174 
0.60 0.2 0.80 14 
 
Study Setting  
HIV-PCR tests on infants <48 hours old took at the Department of Neonatology at Mowbray Maternity Hospital 
(MMH). Specimen draw was conducted at MMH before samples were transported for processing at the National 
Health Laboratory Services (NHLS) laboratory at Groote Schuur Hospital (GSH) as standard of care (SOC). 
MMH is a secondary-level obstetric hospital with neonatal care facilities and a primary care component, 
meaning women with local addresses also deliver at this facility. Recent data indicates that around 11,000 births 
take place each year of which 13% are HIV-exposed and 3.5% of infants are estimated to contract HIV. 
National estimates state that between 60-70% of women using government facilities will require the services of 
a hospital at some point during their pregnancies. Referral to a secondary care facility occurs if the pregnancy is 
deemed to be high risk (irrelevant of HIV status), due to a women’s obstetric history, general medical condition 
or if she presents with specific risk factors during her current pregnancy.   
 
GSH is the current reference laboratory for much of the cape metropole area. HIV-PCR tests are conducted 
using the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 qualitative assay. Approximately 10,000 tests are 
conducted at this laboratory annually, with a test positive rate of ~2% and an indeterminate/equivocal rate of 
~0.5%.   
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The neonatal department performed HIV-PCR tests at birth on infants deemed to be high risk of perinatal 
transmission of HIV as per provincial policy. In 2013 Option B+ (implemented nationally in South Africa) 
permitted clinicians to perform HIV-PCR testing at birth for infants deemed to be high risk of HIV 
transmission, at this time categorization of infants as high risk was subjective to clinician’s judgement. In 2014 
South African National Guidelines recommended the use of HIV-PCR testing at birth for HIV-exposed infants 
at high risk of vertical HIV transmission. High risk status was based on maternal characteristics, primarily late 
or no initiation of ART, clinically documented default status, or if the infant was born preterm or low 
birthweight. This was in line with the WHO technical expert panel that considered universal or risk based birth 
testing in 2013 (Appendix 4). After the successful roll out of high risk birth testing nationally, in late 2015 the 
South African guidelines were updated to include universal testing of all HIV-exposed infants.    
 
Infant and maternal characteristics of those who received HIV-PCR testing within 48 hours of birth were 
recorded in a hospital database.  
 
Data Collection  
The study will be conducted in two phases: Data from 575 infants who received an HIV-PCR test at birth has 
been collated into a hospital database at MMH, infants who received a birth test will be matched to HIV-
exposed infants who did not receive an HIV-PCR test at birth. The study schema is shown in Figure 2. Infants 
will be matched on date of birth as the criteria for receiving a birth tests was altered during the study period. 
Labour ward or theatre birth registers will be used to verify date of birth during the study. Date of birth is 
required to determine test results for infants enrolled in the study. Matching was therefore based on delivery 
method and date of birth.  
 
Phase I – A random sample of 551 HIV-exposed infants who were born at Mowbray Maternity Hospital 
between July 2013 and August 2015 and did not receive a birth test will be matched to infants who received a 
negative result from the HIV-PCR test at birth, using date of birth (within +/- 2 weeks) and delivery method 
(natural vaginal delivery (NVD) or cesarean section (C/S)).  PMTCT register, labour ward and theatre registers 
will be used to identify possible candidates for inclusion. Identified infants will be randomly selected (using 
random number draw if more than one possible match was possible) before retrospective review of routine 
medical records is used to identify key demographic variables. Abstracted chart data to be collected includes 
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(Appendix 3):  
 Maternal demographic information (Name, Address, date of birth, population group, parity) 
 Infant demographic information (Name, date of birth, birthweight, gestation) 
 Maternal Clinical, immunological and virological data prior to labour   
 Choice of feeding method 
 
Phase II – Infant HIV status from HIV-PCR results and date of the test will be determined by review of 
National Health Laboratory Service (NHLS) online record database.  All infants will be followed from the time 
of birth until the initial EID visit. A window period of 4-12 weeks will be specified as returning for routine EID 
testing, but all infants will be given the full study period (to February 2016) to return for follow-up testing. 
Linkage to care will also be determined by review of NHLS databases. Medical records of all infants who 
returned a positive result either at birth or at the 6week test will be reviewed to determine whether a 
confirmatory test was received, and if a further specimen related to HIV care was sent for processing at NHLS 
laboratories signifying linkage to care.   
 
Outcomes of the proposed study will be defined as:   
- EID presentation: mother/infant dyad accessing an HIV-PCR test after being discharged from hospital, 
recorded by HIV-PCR result documented on the NHLS system.  
- Linkage to care: Specimen from an HIV-infected infant sent to the NHLS laboratory and documented on the 




































Figure 2: Study Process: Previously Collected Data: HIV-exposed high risk infants who received a negative result from 
their birth test required further follow up. This data has been collated into a hospital database, infant date of birth will be 
cross referenced to labour and theatre registers before capturing into study database.  
Phase I: HIV-exposed low risk infants are matched on mode of delivery and date of birth to each high risk infant born at 
MMH with a negative birth test result from retrospective folder review. HIV-exposed infants will be identified from the 
PMTCT register and date of birth will be confirmed from labour and theatre registers before folder review for obstetric, and 
maternal socio-demographic characteristics for included infants.  
Phase II will use the NHLS database to identify HIV-PCR results for all enrolled infants and follow up care for all HIV-
infected infants to determine linkage to care. 
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Data Management 
Data management will take place at Mowbray Maternity Hospital, following procedures established for multiple 
previous studies conducted within the hospital site. Data collected on paper forms will be entered into a custom 
designed Microsoft Access database, maintained in a firewall-protected UCT server with nightly backups. The 
study database will be password-protected following standard password protection procedures. All electronic 
files will be encrypted and password protected. Quality control will be through data checking original data 
collection tools or patient folders to identify out-of-range values, logic violations, and missing observations. 
Data editing will be based on reference to the form and/or source document in question; all data queries and 
responses will be logged, and edits will be implemented through separate program files.   
 
Data Analysis  
The data from this study will be analysed using Stata version 13.0 (Stata Corporation, USA). Data will be 
explored using univariate and bivariate descriptive statistics, focusing primarily on maternal characteristics 
stratified by receipt of an HIV-PCR test at birth. Standard approaches will be used (e.g. means with standard 
deviations or medians with interquartile ranges). Frequency tables will be used to examine proportions of HIV-
infected infants, and those who did and did not attend EID testing, comparisons by receipt of birth testing will 
be made.   
  
Objective 1 –To determine associations between maternal characteristics and presentation at routine EID testing, 
bivariate analysis using chi-square tests will be used. The EID statistic (dichotomized for presentation) will be 
the primary outcome of interest analysed using logistic regression to explore independent predictors for EID 
presentation; this will be adjusted for potential confounders including demographics characteristics such as 
maternal age, ART coverage during pregnancy, maternal age, maternal population group, infant birthweight or 
gestation. Outputs will be expressed as odds ratios, with 95% confidence intervals.  
Objective 2 – Proportions of infants with positive HIV-PCR results will be compared to those with negative 
results, this will include comparisons within the group of infants that received a birth test and to those who did 
not.  
Objective 3 – Proportion of infants linked to care after a positive birth test result will be compared to infants 
with positive results at 6 weeks.  
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ETHICAL CONSIDERATIONS  
 
Ethical Approval   
The study protocol and all data collection tools will be reviewed by the University of Cape Town Faculty of 
Health Sciences Research Ethics Committee (UCT-REC). All study procedures will be conducted in accordance 
with the protocol and to the standards of Good Clinical Practice guidelines. The study protocol will be presented 
to Mowbray Maternity Hospital Ethical board for site specific permission for the proposed study.  
 
Potential Benefit 
Participants will not receive any direct benefits; however, exploring the possible impact of introducing a test at 
birth could have wide ranging implication for policy makers. The proposed study could provide evidence around 
the benefits of birth testing to improve care for future HIV-exposed infants. Evidence in favour of birth testing 
could encourage other high burden settings to implement HIV-PCR testing at birth, leading to reduced mortality 
for infants infected in utero. In the event that the evidence shows a negative impact of birth testing, it is hoped 
that the information generated will be used by policy makers to adapt the guidelines and resources to ensure 
health care providers have adequate knowledge and time during PMTCT services to provide care that will 
benefit all HIV-exposed infants and their caregivers. 
 
Potential Harm  
The proposed study will present minimal risk to participants due to the use of routine clinical data during a 
retrospective folder review. Considerable precautions to avert the possibility of loss of confidentiality will be 
taken throughout the process.  
 
Informed consent   
As this is a retrospective folder review, it is not possible to gain consent from participants. Anonymous 
participant identification numbers will be used on all study documents. Collection of participant names and 
other identifiers will only be used for identification of infants to be included in the study. When data collection 
is completed all participant identifiers will be destroyed. As informed consent is not possible in this study, the 
need for confidentiality increases as the only potential risk is loss of confidentiality.  
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Confidentiality 
The following steps will be taken to minimize the risk of any loss of confidentiality throughout study design and 
conduct.  
 All personnel involved in data collection and management will undergo specific training for the study in 
confidentiality and related patient protection issues. 
 Following standard practice, all patient- and study-related information will be kept in locked cabinets at the 
study site. 
 Anonymous participant identification numbers will be used on all study documents. Collection of 
participant names and other identifiers will be destroyed after data collection is completed.  
 All electronic records will be kept in password-protected files. All electronic communications of study data 
will be through password-protected, encrypted files. All data storage at the University of Cape Town will 
be within a firewall-protected SQL server.  
 
Compensation 




The retrospective nature of this study and the collection of data from routine medical records means there may 
be variation in the information collected over the two-year study period.   
Social and demographic factors such as maternal HIV-knowledge, household income, maternal education level 
or distance to clinic that could be associated with non-attendance at EID testing cannot be obtained from folder 
review and will therefore be unavailable for analysis.   
Between July 2013 and October 2015 NHLS database is stratified by province. Before October 2015 study staff 
only had access to data from the Western Cape on the online database. Mother-infant dyads could present for 
care at an alternative facility in a different province and would not be captured, they would therefore be 
recorded as not-attending EID testing in this study, we may therefore overestimate loss to follow up. However, 
we are also unable to ascertain if results were successfully returned to caregivers and therefore may 
overestimate the completion of the EID cascade. We will not be able to determine the date of ART initiation for 
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infected infants and therefore must use a proxy for linkage to care which could overestimate the retention in care 
and linkage to ART.   
This study will not evaluate barriers to follow-up from the patient perspective as no direct contact with 
participants will be made, nor will the study look at completion levels of the whole EID cascade (return for 
testing after cessation of breastfeeding) as timeline for completion of the study would not permit all infants to 
reach the 18 months of age boundary for possible MTCT.  
The study is also not designed to evaluate health system constraints and perspective on knowledge of changes in 
guidelines and reporting of results and HIV-exposure in the Road to Health Card.  
DISSEMINATION OF FINDINGS  
 
The findings from the proposed study will be submitted in partial fulfilment of the requirements for the Master 
of Public Health (General) degree at the University of Cape Town, and to a peer reviewed journal for 
publication. Based on the result of a preliminary analysis an abstract could be submitted to relevant conferences 
for presentation. When analysis has concluded, a report or presentation of the findings can be offered to all 
interested stakeholders.  
BUDGET  
Table 3: Budget calculations for proposed study 
Budget for Proposed Study  
Item  Cost per unit  Number of units  Total cost  
Field Worker R80/hour  50 hours  R4000 
Photocopying  R0.30/page  300 pages  R90 
Data Capture  R60/hour  40 hours  R2400 








































































Departmental and ethical 
approval 
           
Site (MMH) ethical 
approval 
           
Data Capture  
(Previously collected data) 
           
Data Collection  
(Phase 1) 
           
Data Collection  
(Phase 2) 
           
Data analysis 
           
Writing of manuscript 
           
Submission of preliminary 
findings to conference 
           
Submission of dissertation 
           
Dissemination of findings 
           




1.  United Nations Joint Programme on AIDS. the Gap Report. 2014;422. Available from: 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf 
2.  Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and 
uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. Lancet. 
2004;364(9441):1236–43.  
3.  Mayaux M-J, Burgard M, Teglas J, Cottalorda J, Krivine A, Puel J, et al. Neonatal Characteristics in 
Rapidly Progressive Perinatally Acquired HIV-1 Disease. 1996;1–5.  
4.  UNAIDS. 2015 Progress Report On the Global Plan. 2015;11–7.  
5.  UNICEF. Children & AIDS - 2015 statistical update. 2015.  
6.  GBD 2015 HIV Collaborators:, Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, et al. Estimates of 
global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global 
Burden of Disease Study 2015. Lancet HIV. 2016;0(0):1005–70.  
7.  Sidibe M, Singh PK. Thailand eliminates mother-to-child transmission of HIV and syphilis. Lancet 
[Internet]. 2016;352(16):i1619. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27000051 
8.  Tsague L, Abrams EJ. Commentary: Antiretroviral treatment for pregnant and breastfeeding women – 
the shifting paradigm. Aids [Internet]. 2014;28(Suppl 2):S119–21. Available from: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-201403002-
00004 
9.  Myer L, Dunning L, Hsiao NY, Phillips T, Zerbe A, Mcintyre J, et al. Viraemic episodes occur 
frequently in postpartum South African women on ART. In: Conference of Retroviruses and 
Opportunistic Infections. 2016.  
10.  Govender T, Coovadia H. Eliminating mother to child transmission of HIV-1 and keeping mothers 
alive: Recent progress. J Infect [Internet]. 2014;68(SUPPL1):S57–62. Available from: 
http://dx.doi.org/10.1016/j.jinf.2013.09.015 
11.  Barron P, Pillay Y, Doherty T, Sherman G, Jackson D, Bhardwaj S, et al. Eliminating mother-to-child 
HIV transmission in South Africa. Cómo Elimin la Transm del VIH la madre al niño en Sudáfrica 
[Internet]. 2013;91(1):70–4. Available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=84693289&lang=es&site=ehost-





12.  Unaids. GLOBAL REPORT: UNAIDS report on the global AIDS epidemic 2013 [Internet]. Unaids. 
2013. 198 p. Available from: www.unaids.org/.../unaids/.../2013/gr2013/UNAIDS_Global_Report_2013 
13.  Thompson MA, Mugavero MJ, Rivet Amico K, Cargill VA, Chang LW, Gross R, et al. Guidelines for 
improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-
based recommendations from an international association of physicians in AIDS care panel. Ann Intern 
Med. 2012;156(11):817–33.  
14.  Ciaranello AL, Park J-E, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 
diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-
effective interventions. BMC Med [Internet]. 2011;9(1):59. Available from: 
http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-9-59 
15.  World Health Organization (WHO). Recommendations on the Diagnosis of HIV infection in infants and 
children [Internet]. Geneva, Switzerland; 2010. Available from: 
http://whqlibdoc.who.int/publications/2010/9789241599085_eng.pdf 
16.  Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S. A meta-analytic evaluation of the 
polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA [Internet]. 
1996;275(17):1342–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8614121 
17.  Sherman GG, Cooper P a, Coovadia AH, Puren AJ, Jones S a, Mokhachane M, et al. Polymerase chain 
reaction for diagnosis of human immunodeficiency virus infection in infancy in low resource settings. 
Pediatr Infect Dis J. 2005;24(11):993–7.  
18.  Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV 
diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr [Internet]. 
2005;38(5):615–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15793374 
19.  Creek T, Tanuri A, Smith M, Seipone K, Smit M, Legwaila K, et al. Early diagnosis of human 
immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana’s 
national program for prevention of mother-to-child transmission. Pediatr Infect Dis J. 2008;27(1):22–6.  
20.  Lilian RR, Kalk E, Technau K-G, Sherman GG. Birth diagnosis of HIV infection in infants to reduce 
infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis 
   
29 
Journalnfectious Dis J [Internet]. 2013;32(10):1080–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23574775 
21.  Creek TL, Sherman GG, Nkengasong J, Lu L, Finkbeiner T, Fowler MG, et al. Infant human 
immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country 
experiences. Am J Obstet Gynecol. 2007;197(3 SUPPL.).  
22.  Braun M, Kabue MM, McCollum ED, Ahmed S, Kim M, Aertker L, et al. Inadequate coordination of 
maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, 
Malawi. J Acquir Immune Defic Syndr. 2011 Apr;56(5):e122–8.  
23.  Kimario CJ, Schimana W, Charles D, Teri IE, Giphart A, Marlinc R, et al. Abstract 887, page 79: Scale 
up of early infant diagnosis (EID) in Tanzania: experience from the Elizabeth Glaser Pediatric AIDS 
Foundation. The 2009 HIV/AIDS Implementers? Meeting W.  
24.  Hassan AS, Sakwa EM, Nabwera HM, Taegtmeyer MM, Kimutai RM, Sanders EJ, et al. Dynamics and 
constraints of early infant diagnosis of HIV infection in rural Kenya. AIDS Behav. 2012;16(1):5–12.  
25.  Nuwagaba-Biribonwoha H, Werq-Semo B, Abdallah A, Cunningham A, Gamaliel JG, Mtunga S, et al. 
Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in 
Tanzania. BMC Pediatr [Internet]. 2010;10:44. Available from: 
http://www.scopus.com/inward/record.url?eid=2-s2.0-77953548900&partnerID=tZOtx3y1 
26.  Adeniyi VO, Thomson E, Ter Goon D, Ajayi IA. Disclosure, stigma of HIV positive child and access to 
early infant diagnosis in the rural communities of OR Tambo District, South Africa: a qualitative 
exploration of maternal perspective. BMC Pediatr [Internet]. 2015;15(1):98. Available from: 
http://www.scopus.com/inward/record.url?eid=2-s2.0-84940031910&partnerID=tZOtx3y1 
27.  Varga C, Sherman G, Maphosa J, Jones S a. Psychosocial consequences of early diagnosis of HIV status 
in vertically exposed infants in Johannesburg, South Africa. Health Care Women Int [Internet]. 
2005;26(5):387–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16020005 
28.  Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Walusuna L, et al. 
“Wamepotea” (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to 
follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr 
[Internet]. 2011;57(3):e40–6. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3145828&tool=pmcentrez&rendertype=abst
ract 
   
30 
29.  Woldesenbet SA, Jackson D, Goga AE, Crowley S, Doherty T, Mogashoa MM, et al. Missed 
opportunities for early infant HIV diagnosis: results of a national study in South Africa. J Acquir 
Immune Defic Syndr [Internet]. 2015;68(3):e26–32. Available from: 
http://www.mendeley.com/catalog/missed-opportunities-early-infant-hiv-diagnosis-results-national-
study-south-africa-6/ 
30.  Lilian RR, Kalk E, Bhowan K, Berrie L, Carmona S, Technau K, et al. Early diagnosis of in utero and 
intrapartum HIV infection in infants prior to 6 weeks of age. J Clin Microbiol. 2012;50(7):2373–7.  
31.  Sherman G. HIV testing during the neonatal period. S Afr J HIV Med. 2015;16(1):2–4.  
32.  Hsiao N-Y, Dunning L, Kroon M, Myer L. Laboratory evaluation of the Alere q point-of-care system 
for early infant HIV diagnosis. PLoS One. 2016;11(3).  
33.  UNAIDS:Technical Report. HIV/AIDS Diagnositc Landscape 2014. 2014.  
34.  Lilian RR, Johnson LF, Moolla H, Sherman GG. A mathematical model evaluating the timing of early 
diagnostic testing in HIV-exposed infants in South Africa. J Acquir Immune Defic Syndr [Internet]. 
2014;67(3):341–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25118910 
35.  Francke J, Ciaranello AL. Clinical impact and cost effectiveness of early infant HIV diagnosis in South 
Africa: Test timing and frequency. JID- Prepublication. 2016.  
36.  Davies M-A. Research gaps in neonatal HIV-related care. South Afr J HIV Med [Internet]. 2015;16(1):6 
pages. Available from: http://www.sajhivmed.org.za/index.php/hivmed/article/view/375/479 
37.  Davies MA, Pinto J. Targeting 90-90-90 - Don’t leave children and adolescents behind. J Int AIDS Soc. 
2015;18(Suppl 6):1–6.  
38.  South African National Department of Health. National Consolidated Guidelines for the Prevention of 
Mother-To-Child Transmission of HIV (PMTCT) and the I of HIV in Children, Adolescents and Adults. 
2015;(April):1–128.  
39.  Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited 
antiretroviral therapy versus deferred therapy in South African infants infected with HIV: Results from 
the children with HIV early antiretroviral (CHER) randomised trial. Lancet [Internet]. 
2013;382(9904):1555–63. Available from: http://dx.doi.org/10.1016/S0140-6736(13)61409-9 
40.  World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: recommendations for a public health approach. Switzerland; 
2016.  
   
31 
41.  Woldesenbet SA, Jackson D, Goga AE, Crowley S, Bs MB, Doherty T, et al. Missed Opportunities for 
Early Infant HIV Diagnosis : Results of A National Study in South Africa. J Acquir Immune Defic 
Syndr. 2015;68(3):26–32.  
42.  Maritz J, Hsiao N, Presier W, Myer L. Low Uptake of Routine Infant Diagnostic Testing Following 
HIV PCR Testing at Birth. In: Conference of Retroviruses and Opportunistic Infections. 2016. p. Poster 
Presentation.  
43.  Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a 
systematic review. PLoS Med. 2011 Jul;8(7):e1001056.  
44.  Sibanda EL, Weller IVD, Hakim JG, Cowan FM. The magnitude of loss to follow-up of HIV-exposed 
infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic 
review and meta-analysis. AIDS. 2013;27(17):2787–97.  
45.  Geddes R, Giddy J, Butler LM, Van Wyk E, Crankshaw T, Esterhuizen TM, et al. Dual and triple 
therapy to prevent mother-to-child transmission of HIV in a resource-limited setting - lessons from a 







   
32 




Enormous progress has been made towards tackling the HIV/AIDS epidemic, especially in low-income 
countries (1), but the global target to end AIDS by 2030 is an ambitious goal. Since the passing of the 
millennium development goal target date in 2015, UNAIDS has led the efforts to establish new targets for the 
scaling up of HIV-treatment (2). The new three part 90-90-90 target aims to identify 90% of all people living 
with HIV, treat 90% of those diagnosed with HIV infection and achieve virologic suppression in 90% of all 
individuals receiving antiretroviral treatment (ART) by 2020 (2,3). Previous changes in treatment regimes have 
increased the CD4 count threshold for initiation of HIV treatment in low income countries with almost all 
countries now adopting Option B+ (lifelong ART for all pregnant and breastfeeding women irrespective of 
CD4+ count) and slowly moving towards “test and treat”, which modelling studies predict could be effective at 
reducing HIV transmission at a population level (4,5). The aim of the new global targets is to identify new 
infections, and provide high quality care to those living with HIV. Focus has been placed on retaining patients 
in care and achieving sustained virological suppression in order to reduce the morbidity and mortality associated 
with HIV infection (6,7). The same targets have been proposed for children, with the ideal of complete 
elimination of mother to child transmission leading to the emergence of an AIDS free generation, but in high 
burden settings, especially sub-Saharan Africa, programmes centred on diagnosis and treatment of infected 
infants continue to have the largest shortfalls (7–9).  
 
South Africa has been a leader in the prevention of mother to child transmission (PMTCT) programmes, 
remarkably reducing the vertical transmission of HIV. Yet early infant diagnosis (EID) testing coverage reached 
only 72.6% of HIV-exposed infants in 2012 (10), and the linkage to care for infected infants was only 71% (11). 
Globally this was far worse, with only 49% of all HIV-exposed infants receiving a virologic test before 6 weeks 
of age in 2014 and only 30% of infected infants being effectively linked to care to initiate ART (12,13). Infected 
infants are known to be at high risk of mortality within the first year of life (14). Prompt initiation on ART has 
been shown to increase infant survival, but, without treatment, 50% will die before their second birthday (12). 
Despite the large-scale implementation of PMTCT and the pivotal role of EID within these programmes, the 
progress of infected infants is lagging far behind that of adults and the global targets for 2020 (7). 
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Understanding the gaps in HIV-related infant care, particularly around the retention of those HIV-exposed 
within the continuum of PMTCT services, allowing for diagnosis and treatment of infected infants remains one 
of the most important areas of investigation (8). The following review will explore the various factors relating to 
diagnosis, treatment and retention in care for HIV-exposed infants, along with barriers to presentation at EID 
testing.  
OBJECTIVES OF THE LITERATURE REVIEW 
The objective of this review is to examine major themes in the existing literature on HIV-testing in infants, 
looking specifically at the timing and frequency of tests, recent changes to local and global recommendations 
whilst also exploring the barriers to attaining sufficient coverage of EID testing. The review is also intended to 
assess the empirical evidence currently available and assess whether this is sufficient to help implement 
programmatic changes in National early infant diagnosis programmes.   
 
LITERATURE SEARCH 
Literature was collected by searching Medline (via Pubmed) Google Scholar and EMBASE databases for peer 
reviewed or non-peer reviewed publications using key words such as ‘human immunodeficiency virus or HIV’ 
‘infant HIV’ ‘antiretroviral therapy’ ‘early infant diagnosis’ ‘perinatal transmission’ and ‘birth testing’ (full 
search terms included in appendix 10). There were no restrictions for geographical location or date applied. 
Only articles in English were included. All titles were screened and abstracts of relevant articles were read to 
identify full-texts for review. Articles were excluded if they examined effectiveness of specific ART drug 
regimes or assessed diagnosis of infants older than 18 months. In addition, the reference lists of relevant articles 
found were examined for any further texts. Conference abstracts for the Conferences of the International AIDS 
Society (2010 to 2016) and the Conference on Retroviruses and Opportunistic Infections for (2014/2015/2016) 
were searched to identify recent studies that may not yet have been published as full text. (Summary table of 
included studies attached as appendix 9). 
SUMMARY OF THE LITERATURE 
Global HIV/AIDS epidemic  
It is estimated that over 36 million people were living with HIV globally in 2015, 71% of whom live in sub-
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Saharan Africa (13). While the vast majority of new HIV infections in sub-Saharan Africa occur in adults, 
young women are disproportionately affected by HIV. Consequently, 1.2 million children were born exposed to 
HIV in 2013, all of whom required an HIV test during infancy (13, 14). In sub-Saharan Africa, an estimated 
200,000 infants were infected with HIV in 2014, almost 90% of the global total, but with only 49% of HIV-
exposed infants receiving a virologcal test, mortality rates for  infected infants remain unacceptably high (4).  
  
Prevention of mother to child transmission (PMTCT)  
Women’s access to antiretroviral treatment during pregnancy has increased extensively since 1994 with greater 
understanding around the pathogenesis of the virus and possible treatment mechanisms. Initially zidovudine was 
shown to reduce the risk of perinatal transmission by the PACTG 076 trial (15), followed by combined 
antiretroviral treatment in the late 1990’s (16–18). Prevention of mother-to-child transmission (PMTCT) 
programmes no longer restrict access to medication based on the woman’s health status, but rather, all HIV-
infected pregnant women, irrespective of CD4+ count or clinical disease stage are initiated on lifelong ART 
treatment (19,20). Globally there have been major increases in the percentage of women receiving ART during 
pregnancy between 2000-2014, with substantial increases seen since the introduction of Option B+ in 2013 
(21,22). Prior to ART use in pregnancy, over 25% of exposed infants would acquire HIV during pregnancy, 
labour or the postpartum period, but with access to ART, the transmission rate has dropped to below 2% in 
many settings, including Thailand and Cuba which have been certified by the WHO as having eliminated 
mother to child transmission of HIV (1,23,24).  Yet despite the significant advances in PMTCT, vertical HIV-
infection in infants continues to occur with an estimated 16,000 infants being diagnosed with HIV in South 
Africa in 2013 (4).  
Diagnosis of paediatric HIV: Early Infant Diagnosis (EID)  
The mortality rates of infected infants depends both upon the timing of HIV infection and the initiation of 
treatment. Perinatally infected untreated infants are at highest risk of rapid disease progression and mortality, 
with one in two untreated HIV+ infants dying before 2 years of age (25–27). In 2008, the Children with HIV 
Early ART (CHER) trial provided evidence that initiating treatment before 3 months of age reduced mortality 
by 76%, compared to waiting until clinical symptoms of AIDS or advanced immunosuppression developed (28). 
In order to benefit from very early ART initiation, infants must first be diagnosed with HIV, as a result, the 
World Health Organization (WHO) now recommends that HIV-exposed infants be tested by six weeks of life 
and those who test positive should be immediately be referred for initiation of ART (29,30).   
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 PCR as a tool for EID  
Inexpensive serological antibody assays that are routinely used for diagnosis in adults cannot be easily 
interpreted for HIV-exposed infants. Trans-placental transfer of maternal antibodies leads infants to be 
seropositive until 18 months of age (31,32). Infants under the age of 18 months require nucleic acid 
amplification tests (NAAT) to diagnose HIV infection. These assays recognize viral nucleic acids (HIV RNA or 
DNA), rather than anti-HIV antibodies produced as an immune response to infection by HIV.  NAAT 
(otherwise known as polymerase chain reaction (PCR)) assays are more complicated, time consuming and 
costly than serological assays, but they have been shown to be both sensitive and specific in the detection of 
paediatric HIV infection (33,34).  
 
Barriers to EID testing  
NAAT tests require specimens to be stored in coldchain, and are typically performed using specialist laboratory 
equipment by highly trained personnel. Access to EID is therefore severely limited in many countries to 
locations with centralized facilities with UNAIDS estimating that of the 1.2 million HIV-exposed infants born 
in high burden settings, only 49% received a virological test in 2014 (35). Approaches to decentralize EID 
programmes and subsequently increase access to virological tests have been prioritized by the WHO and 
governments of countries with a high burden of paediatric HIV. Investments have been made in infrastructure 
and human resources to strengthen laboratory systems and transportation networks (36), whilst protocols of 
using dried blood spot (DBS) as means of specimen collection have decentralized testing and helped expand the 
coverage of EID in several high burden countries (37,38). DBS sample collection has no phlebotomy 
requirements, and specimens can be transported from peripheral sites to a central laboratory without 
refrigeration for up to 15 days, providing a cost-effective solution in resource-limited settings (13,37,38). 
Studies carried out in Cameroon, Tanzania, India, Côte d’Ivoire and South Africa have shown assays using DBS 
samples are highly sensitive and specific for infant HIV diagnosis and have been an important facet in the 
successful scale up of EID activities (39–42).  
 
Cost and availability are not the only barriers to implementing successful EID programmes. Diagnosing 
paediatric HIV requires multiple clinic visits from mother infant dyads with each step providing an opportunity 
for infants to be lost from care. Edmonds et al describe difficulties in maintaining optimal service delivery at 
decentralized settings whilst Ciaranello et al. describe LTFU within the EID cascade, including the acceptance 
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of testing at a healthcare facility for HIV-exposed infants, specimen collection, transport, laboratory processing 
and results return to both healthcare providers and then infants’ caregivers, with linkage to care to initiate 
antiretroviral therapy required for infected infants (Figure 1) (32).   
 
Experiences from the PMTCT cascade in low resource settings have shown both structural and operational 
aspects of the health system can lead to LTFU. A study from South Africa found women were more likely to 
both access and be retained in care if they were receiving treatment at a local clinic, whilst a study from 
Ethiopia suggested that patient load also has an effect on retention (43,44). Operationally it is known that the 
EID process can take months. In Kenya, Tanzania and Cote D’Ivoire samples took between 1-3 months to be 
returned to caregivers after the initial specimen collection had taken place (32,45,46). In South Africa, this has 
been found to be much quicker taking a maximum for 2 weeks for results to be returned to caregivers at primary 
care, and a matter of days in higher level facilities (47). Without point-of-care technology, which is not yet 
widely available for EID, the cascade requires multiple visits (48,49). Spanning these visits months apart could 
cause high levels of loss to follow up within the EID cascade. Even when results are available at clinics, there is 
often inadequate result return to caregivers. Patients often move between facilities or geographical areas and do 
not return to their original clinic, others fail to return to care at all and therefore are unable to receive the test 
result.  
As EID programs are incorporated in both PMTCT and pediatric programs, many settings have failed to find 
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infected infant to care 
 
Figure 1. EID Cascade: Multiple steps are required to complete the EID cascade before caregivers are 
informed of an infant’s final status. Infant’s with a negative result remain HIV-exposed until the cessation 
of breastfeeding. (Adapted from Ciaranello 2011) 
   
37 
Ultimately the loss to follow up and delay in result return can prove fatal to infected infants; a study in Tanzania 
found that only 55% of caregivers returned for the result, and 14% of caregivers were returned a positive result 
after their infant had demised (50), with a more recent South African study finding 20% of HIV infected infants 
had either died or been lost to follow up by 6 weeks of age (51).   
 
There is widespread recognition that every new paediatric HIV infection is the result of one or more 
shortcomings within the health system, but all too often there is limited response to a new infection. EID 
programs are incorporated in both PMTCT and pediatric programs, but the overlap leads to no single entity 
taking responsibility for result return and initiating action as and when required (52). 
Barriers to retention are not only facility based. Individual, socioeconomic and psychosocial factors have been 
linked to LTFU in the PMTCT/EID cascades (53). As caregivers bear ultimate responsibility for EID 
presentation it is important to consider all possible influences on LTFU. Individual factors such as attending 
PMTCT services during pregnancy and illicit drug use have both been shown to reduce presentation at EID 
testing (54,55). These could be acting as proxies for health seeking behavior in women living with HIV. The 
most frequently cited barriers to EID presentation are sociodemographic factors; HIV knowledge, education 
level, maternal age and marital status have all been associated with lower presentation to HIV care (54,56,57).  
Ndondoki et al found that in Côte d’Ivoire acceptance from mothers was relatively high but paternal acceptance 
of EID testing was low, and social etiquette still dictates a key role for fathers in the decision making around 
infant health in west Africa. Stigma surrounding HIV also remains a huge barrier to women accessing treatment 
and preventing further transmissions, Braitstein, et al. described how women living with HIV struggle with fear 
of discrimination, a lack of autonomy and support from family and or the community which prevents many 
from disclosing their status. In Tanzania this was shown to be associated with not attending the HIV clinic (58). 
  
Timing and frequency of HIV PCR testing in infants  
Thanks to the expansion of PMTCT programs, a greater proportion of HIV-exposed infants will return a 
negative result. This can in turn provide reassurance to families (59,60), whilst providing integral surveillance 
data for the assessment of PMTCT programme effectiveness (42), but the main function of EID is to initiate 
infected infants on treatment. South African EID protocols schedule EID visits of specimen collection and result 
return to coincide with the early immunization visits at 6, 10 and 14 weeks of age, simplifying the logistics for 
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caregivers and reducing the number of postnatal follow up visits required (19). However, in the context of high 
infant and maternal prophylaxis, a single PCR test performed at 6 weeks of age may have reduced sensitivity 
and therefore fail to detect some in utero and intrapartum infections (51,61). Testing at 6 weeks of age is 
therefore too early to detect all infected infants when PMTCT coverage is high, but infants infected in utero are 
susceptible to rapid disease progression, with recently published data has showing the peak age of HIV-related 
mortality occurs around 8-12 weeks of age (62–64) This indicates that testing at 6 weeks is also too late to 
intervene before many infected infants demise (61). Further evidence from observational studies is needed to 
inform the optimal timing of EID testing in the first few weeks of life. This would need to consider, assay 
sensitivity, morbidity and mortality of infants and retention in care. 
HIV PCR testing at birth 
In the developed world, where there is a low prevalence of HIV, and ample access and availability of resources, 
guidelines recommend testing HIV-exposed infants at numerous time points during the neonatal period (8,65), 
but in South Africa and other high burden settings this is neither logistically or economically possible. Infants 
receive only one virological test during infancy followed by serological assay after the cessation of 
breastfeeding (29,66).  
In 2012 Lilian et al demonstrated that 76% of all early HIV infections were detectable at birth (51), an increase 
to the yield found in previous studies (32). Improved PMTCT coverage at delivery has increased the proportion 
of in utero infections relative to intra-partum and very early post-partum infections that are identified by EID 
testing (67). More infants are detectable at birth and HIV-PCR testing within hours of delivery has become a 
more attractive option. However, birth testing necessitates a second test to detect the 25% of missed infections 
at birth and all intrapartum infections.  
A recent modelling study evaluating the timing of early infant diagnosis concluded that performing a PCR test 
at birth and then again at 10 weeks would likely be the ideal diagnostic algorithm in South Africa (68). Further 
modeling studies have found this algorithm to be cost effective if result return occurs at scale on a reasonable 
timeline (61, Franke et al. Pre-publication). These studies take into account that in South Africa, 95% of women 
receive an HIV test and result during pregnancy, over 90% have a skilled birth attendant present at delivery and 
almost 70% of HIV-exposed infants are born to mothers who received ART during pregnancy (70). Although 
the CHER trial provided clear evidence around earlier initiation of ART in infants, there are no studies that have 
examined the mortality benefit for infants initiating ART within the first days of life. Cases that mirror that of 
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the Mississippi baby have forged a consensus from clinicians that initiating treatment earlier has the potential to 
lower viral reservoirs and prevent disease progression in early infancy (71,72), moreover no data exists around 
very early ART in premature or low-birthweight infants.   
 
In 2013 South Africa adopted Option B+ for PMTCT programmes on a National scale. The PMTCT guidelines 
permitted clinicians to perform HIV-PCR testing at birth for infants deemed to be high risk of HIV 
transmission. The deviation from the EID testing algorithm at the time allowed for earlier treatment of infected 
infants or initiation of cARP for those with negative results at birth. It was an attempt to address the high level 
of childhood mortality associated with HIV. However, at this time categorization of infants as high risk was 
subjective to clinician’s judgement.   
 
In considering the limitations regarding 6 week testing, the perceived benefit from very early initiation of ART, 
and the current caveat option of birth testing within the PMTCT guidelines for Option B+, the 2014 South 
African National Guidelines recommended the use of HIV-PCR testing at birth for HIV-exposed infants at high 
risk of vertical HIV transmission (19). High risk status was based on maternal characteristics, primarily late or 
no initiation of ART, clinically documented default status, or if the infant was born preterm or low birthweight. 
This was in line with the WHO technical expert panel that considered universal or risk based birth testing in 
2013. After the successful roll out of high risk birth testing nationally, in 2015 the South African guidelines 
were updated to include universal testing of all HIV-exposed infants. Over the previous year birth testing had 
been more commonly carried out in higher level facilities where health care professionals were more likely to be 
aware of high risk criteria (73), however the high risk criteria took into account risk factors for HIV 
transmission, and not simply in utero transmission, which lead to the vast majority of test results returned to be 
negative. Programmatically it may be easier for health care professionals to implement a universal policy 
effectively rather than restrict testing to high risk infants (8,61).   
 
Barriers to birth testing  
Loss to follow up (LTFU) has been well documented across the EID cascade in low resource settings, with 
evidence of LTFU occurring at each stage in the cascade (32). Adding additional steps to an already 
complicated cascade could result in attrition of routine EID services compared to the uptake when no birth test 
is available. An observational study from the Western Cape found that only 49% of infants returned for follow 
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up testing having previously received a birth test, far below the national estimates of EID coverage (74). There 
are recognsied weaknesses in the provision and uptake of PMTCT services during the post-partum period for 
women living with HIV and their newborn infants. Yet, there remains a paucity of data available on why mother 
infant dyads who do present to care for testing are lost from follow up visits further down the cascade 
(35,75,76). Woldesenbet et al. describe how inadequate maternal knowledge, fear of discrimination and lack of 
provider led counseling contributed to missed opportunities for EID in South Africa. Kenyan and Tanzanian 
studies report mortality to be a key reason for LTFU as well as disclosure, fear and not wanting to upset family 
members (56,77–79). Considering the scale of LTFU within the cascade it is surprising that more is not being 
done to examine and address these concerns to facilitate mother/infant dyads being retained in care.    
 
PMTCT services are designed to offer support to women living with HIV, and provide them with information 
for both antenatal and postnatal care. Although much literature exists about the effectiveness of PMTCT 
programmes, there has been little research conducted into the quality of counseling provided around post-
partum care. A report by the WHO details how counseling is provided by often busy, overworked staff 
members, who focus on the initial HIV test result and ART treatment. Despite numerous opportunities for 
follow up counseling, provision of accurate information about postpartum care including infant feeding and 
infant testing remains limited (60,79–81).  
Linkage to care for infected infant  
The substantial losses in retention of mother infant dyads from the cascade results in an extremely low number 
of infected infants linking to care. In 2014, UNAIDS estimated that of the 2.6 million children living with HIV 
globally, only 32% were receiving ART. This does not account for the hundreds of thousands more who died as 
a result of the disease. For HIV-infected infants the time between their HIV-test result and linkage to care is 
critical because of the rapid disease progression during the early weeks of life (82). Accessing antiretroviral 
treatment could allow children to survive into adolescence. However, a study in Cape Town, South Africa found 
that only 71% of HIV-infected infants who presented to care for EID testing were linked to care (11). In Malawi 
this figure was much lower at 36% of infected infants receiving ART (83, 84). Although many studies associate 
mortality with becoming lost to follow up after a positive test result, or, low result return to caregivers, a study 
from Kenya found that 30% of HIV-infected infants had not returned to the clinic for care because of disclosure 
issues including fear of family or community discrimination (47,56).  In South Africa, although access to EID 
testing is high, not all clinics who offer testing are able to provide paediatric ART services (11). The 
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requirement for further clinic visits could not only increase the opportunity for loss to follow up to occur, but 
presents further worries around stigma and fear of discrimination for families (85). It is clear that there is a 
greater need to understand the reasons for infants becoming lost to follow up from a caregivers perspective in 
order to implement successful programmes integrating PMTCT, EID and childhood ART services that can 
achieve greater retention in care.  
 
IDENTIFICATION OF GAPS IN THE LITERATURE  
 
It is evident in the literature from high and low burden countries, that initiating earlier treatment to HIV-infected 
infants will increase survival, but there are a range of barriers which prevent complete coverage of EID testing, 
around costs and health system constraints, as well as loss to follow up across the cascade. In South Africa it is 
known that caregivers and infants fail to attend EID testing as a result of lack of HIV knowledge or as a result of 
the social context in which they live. Stigma is still abundant around HIV and many women suffer from a fear 
of discrimination that prevents them from seeking follow up treatment. There is a need to improve support and 
counseling services provided to women living with HIV during pregnancy to improve their understanding of 
HIV transmission, especially during the post-partum period.  
 
Further evidence is also needed around testing during the neonatal period, possible attrition of services at 6 
weeks, and whether this is the optimum time for follow up testing. This study aims to contribute to the growing 
body of literature around birth testing. Due to the limited evidence around diagnosis and treatments of HIV-
infected infants immediately after birth, the WHO guidelines provide only a conditional recommendation to 
consider the use of birth testing as an additional test to the EID cascade. South Africa is therefore the first high 
burden country to implement universal birth testing for all HIV-exposed infants, but other countries such as 
Swaziland are soon to follow suit. Since there are very few published studies, public health programmes have 
little evidence on which to base their birth testing policies, and as a result there has been no change to 
counseling or result return procedures since the addition of an HIV-PCR test a birth.   
 
Exploring the possible impact of introducing a test at birth could have wide ranging implication for policy 
makers. Birth testing could be shown to successfully link infected infants to care earlier, or with a greater yield 
   
42 
than currently seen at 6 weeks by bypassing possible losses associated with mortality or loss to follow up. 
However, it is also possible that introducing birth testing could have a profound effect on those infants that 
experience intra-partum infections, who may be less likely to return for follow up testing or subsequently link 
to care having previously received a negative result. Understanding the impact of introducing a birth test could 
allow policy makers to adapt the guidelines and resources to ensure PMTCT and EID programmes are effective 
for all HIV-exposed infants. 
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Introduction: PCR testing at birth (‘birth-testing’) is suggested by new World Health Organization guidelines 
for rapid diagnosis of infants infected with HIV in utero. However, there are few data on the implementation of 
this approach in sub-Saharan Africa and whether birth-testing affects uptake of subsequent routine early infant 
diagnosis (EID) testing at 6-10 weeks of age is unknown.  
 
Methods: We reviewed 575 consecutive infants undergoing targeted high-risk birth-testing in Cape Town, 
South Africa, and matched those testing HIV-negative at birth (n=551) to HIV-exposed infants who did not 
receive birth-testing (n=551). Maternal and infant clinical and demographic data, including EID testing uptake, 
were abstracted from routine records. Data were analyzed using logistic regression models, examining 
independent predictors of presentation at follow-up EID testing. 
 
Results: Overall 3.8% of all birth-tests conducted were positive, while later EID testing positivity rates were 
0.5% for those infants testing HIV-negative at birth and 0.4% for those without birth-testing. Infants who 
underwent birth-testing were less likely to present for later EID compared to those without a birth-test (73% vs 
85%; p<0.001). This difference persisted after adjusting for maternal and infant characteristics (adjusted odds 
ratio,0.60 95% confidence interval, 0.40-0.88) and across demographic and clinical subgroups. Infants 
undergoing birth-testing also presented for later EID at a significantly older age (mean age 60 vs 50 days, 
p<0.001).  
 
Conclusions: While the yield of targeted high-risk birth testing in this setting appears high, neonates testing 
HIV-negative at birth may be less likely to present for subsequent EID testing. For birth-testing implementation 
to contribute to overall EID programme goals, structured interventions are required to support follow-up EID 
services after negative birth-test results. 




Prevention of Mother-to-Child Transmission (PMTCT) programmes have been one of the hallmarks of success 
in the fight against HIV/AIDS (1). In South Africa, access to antiretroviral therapy (ART) during pregnancy and 
infancy has steadily increased, leading to a 76% reduction in new infections among children (1). Currently, 
lifelong ART is available to all pregnant or breastfeeding women regardless of CD4 count or clinical stage of 
infection (2,3). Yet challenges remain in eliminating mother-to-child transmission (MTCT), with over 16,000 
new paediatric infections detected in 2015 (4). It is known that those who acquire HIV in utero (IU) are at 
highest risk of morbidity and mortality (5), but strong evidence from the CHER trial indicated that prompt 
diagnosis and early introduction of ART can dramatically reduce mortality, disease progression and 
neurodevelopmental impairment in children infected with HIV (6,7). Early infant diagnosis (EID) is the key 
strategy for identifying infected infants and linking them to care. In high burden settings, however, coverage 
remains limited and the proportion of infected infants receiving treatment is below both adult rates and global 
targets (8–10).  
 
Currently the World Health Organization (WHO) recommends HIV-exposed infants be tested by six weeks of 
life, with those who test positive being immediately referred for initiation of ART (11,12). Virological tests 
(HIV-PCR) required by infants for diagnosis of HIV are expensive for the health system and also require mother 
infant dyads to complete multiple clinic visits often spanning several months (13,14). Delays between sampling 
and return of test results may cause loss to follow-up (LTFU) and, consequently, fail to link many infants to life 
saving ART before the peak age of mortality at 11 weeks (15,16).   
 
Although there are limited data on diagnosis and treatments of infants immediately after birth, there is 
consensus amongst clinicians that early initiation of ART has the potential to limit viral reservoirs and prevent 
disease progression early in infancy (17–19). It is argued that as ART coverage during labour increases the 
proportion of vertical infections that occur in utero increase relative to intra-partum infections (20). With high 
levels of LTFU in routine EID, a successful birth testing regime detecting 76% of all early vertical transmissions 
could increase the proportion of infected infants linked to care. A follow up test scheduled between 6-10 weeks 
of age would be required to diagnose intra-partum and very early post-partum transmissions undetectable at 
birth (21,22). In 2014, South African National Guidelines recommended the use of HIV-PCR testing at birth for 
   
55 
HIV-exposed infants at high-risk of vertical HIV transmission. High risk status was based on maternal 
characteristics, primarily late or no initiation of ART, clinically documented default status, or if the infant was 
born preterm or low birthweight (23). In mid-2015, the guidelines were further updated to include routine HIV-
PCR testing at birth for all HIV-exposed infants (2).  
 
Delivery of postnatal services and retention in care are recognized as weak links in the continuum of care for 
women and their infants accessing PMTCT services. Lack of knowledge and understanding of the need for 
infant testing are often cited as reasons for non-attendance at EID testing (24). The addition of an extra test to an 
already complicated cascade could result in attrition of routine EID services compared to the uptake when no 
birth test is available. Recent estimates indicate that only 49% of infants presented for follow-up EID testing 
after a negative PCR result at birth, far below the national estimates of EID coverage (25). We examined 
whether there is an impact from including a birth test within the EID testing protocol and looked to identify 
possible infant and maternal factors associated with presentation at EID testing.  
METHODS 
This study was a retrospective cohort study including 1,126 mother-infant dyads conducted at a single-site in the 
Western Cape Province, South Africa. All infants were delivered at Mowbray Maternity Hospital (MMH) 
between July 2013 and August 2015. MMH is a secondary-level obstetric hospital with neonatal care facilities. 
Of the 11,000 infants born at MMH each year, 13% are HIV-exposed and 2% are HIV-infected (14) (Ref Max 
Kroon Personal Correspondence). National estimates state that between 60-70% of women using government 
facilities will require the services of a hospital at some point during their pregnancies. Referral to a secondary 
care facility occurs if the pregnancy is deemed to be high risk, due to a women’s obstetric history, general 
medical condition or if she presents with specific risk factors during her current pregnancy (26,27). MMH also 
has a primary care component allowing women with local addresses to deliver on site.  
 
During the study period, all mothers were eligible for Option B+ (ART for all pregnant and breastfeeding 
women irrespective of CD4+ count). HIV-PCR testing at birth was targeted at infants identified as being at high 
risk of vertical transmission as per local guidelines. High-risk status was based on maternal characteristics, 
primarily unsuppressed viral load, late or no initiation of ART or known non-adherence during pregnancy 
(clinically documented default status), or infant characteristics (symptomatic, preterm delivery or if the infant 
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was abandoned). Birth tests occurred within 48 hours of delivery, and result return occurred prior to discharge. 
Provincial guidelines for the study period required all HIV-exposed infants to undergo HIV-PCR testing at 
routine postnatal immunization visits at 6 weeks of age. Interim HIV screening also occurred in children who 
presented to hospitals with opportunistic infections or symptoms related to HIV. The results of all HIV-PCR 
tests are hosted in the central data warehouse of the National Health Laboratory Service (NHLS), the sole 
provider of pathology services for the public health sector in South Africa. 
All infants delivered at MMH who underwent a birth test were enrolled in the study. Infants with negative birth 
PCRs were matched on date of birth and mode of delivery to HIV-exposed infants who did not receive an HIV-
PCR test at birth. Maternal antenatal features and obstetric characteristics of all neonates were abstracted via 
folder review from data collected routinely in the hospital for clinical monitoring and evaluation purposes. 
Using folder number, name, date of birth and maternal address, we identified the first HIV-PCR result on the 
NHLS system for each HIV-exposed infant before February 2016. All infants were given the complete time 
period of the study to return for testing.    
 
Written informed consent was not feasible because of the retrospective nature of the research. All data was 
handled confidentially throughout the research process. The study, including waiver of informed consent was 
approved by the Human Research Ethics Committee of University of Cape Town Faculty of Health Sciences 
and the Mowbray Maternity Hospital Research Committee.   
 
Data analysis  
Data were analysed using Stata Version 13.0 (Stata Corporation, College Station, Texas, USA). We described 
patient characteristics using summary statistics, presented using mean/median or frequencies as appropriate. 
Associations between categorical variables were calculated using chi-squared tests whilst the Wilcoxon rank-
sum test was used for continuous variables. The age of infants at follow up testing was calculated using their 
specimen date and their date of birth from labour or theatre registers at MMH. We defined EID presentation as 
mother/infant dyad accessing an HIV-PCR test after being discharged from hospital, with results hosted on the 
NHLS system. Analyses examined the characteristics of the infants included in the study by receipt of birth 
testing. Logistic regression models were used to examine the independent predictors of returning for an HIV-
PCR test. The results are presented as odds ratios (OR) with 95% confidence intervals (CI). Variables in the 
model were selected based on prior evidence and findings from descriptive statistics. We defined a secondary 
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outcome, linkage to HIV care, as an infected infant having a specimen related to HIV care (eg. HIV RNA, CD4, 
viral load, etc.) sent to the NHLS for processing by either 3 or 6 months after the date of the positive EID assay. 
RESULTS 
 
Overall, 1,126 HIV-exposed infants were followed from birth until February 2016. Of these, 575 neonates 
underwent birth testing, of whom 4% (22) received a positive result, 0.3% (2) returned equivocal results and 
96% (551) received negative results. Reasons for being considered at high risk of perinatal transmission of HIV 
and therefore receiving a birth test ranged from maternal characteristics, to abandonment, low birthweight or 
preterm birth. Table 1 lists the most common reason for receiving a birth test to be lack of maternal ART 
coverage during pregnancy, which was associated with 50% (286) of HIV-PCR tests performed at birth. This is 
followed by recorded maternal default on treatment and high viral load attributing to 28% (163) of infants 
receiving a birth test. One fifth of infants (119) were included due to low birthweight or preterm birth. No 
reason was stated for 6% (37) of infants who underwent a birth test.   
 
Infants who had negative birth test were matched to 551 infants who did not receive birth testing. The 
demographic characteristics of the infants followed up for subsequent testing are summarized in Table 2. Of the 
1,102 study subjects analysed, there were no differences found between the two groups with regards to infant 
sex, infant feeding mode or gravidity. Just over half, 50% (555) were female, and 53% (582) of all infants were 
delivered by normal vortex delivery. Over three quarters, 77% (843) of all mothers had previously given birth, 
and 82% (898) exclusively breastfed their infant. Clinical differences in the two groups could be found for 
maternal age, gestation and infant birthweight, which were all part of the criteria used to identify infants at high 
risk of HIV transmission. Maternal age ranged from 15 years to 48 years, with mean maternal age of 28.2 years 
for infants who underwent a birth test compared to 29.2 years for those infants who did not. Fewer infants who 
underwent a birth test were term gestation (73% (401) vs 88% (486)) and birthweight >2500g (66% (363) vs 
92% (506)) than those who did not undergo a birth test. Maternal population group also differed, more infants 
were born to mothers identifying as black African in the cohort who did not receive a birth test compared to 
those who did (82% (433) vs 79% (454)).  Available CD4 count also varied between the two groups, but 87% 
(481) of CD4 data for infants who did not undergo birth testing were unavailable due to changes in hospital 
reporting practices.   
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Of the 551 birth-tested infants who received a negative result at birth, 73% (401) presented for follow-up EID. 
Of the 551 not birth-tested, 85% (470) presented for follow-up EID, p<0.001. EID testing occurred at a 
significantly older age in birth-tested compared to not birth-tested infants: mean age 60 vs. 50 days, p<0.001. 
The proportion of positive results was lower at follow-up testing than at birth: 0.5% (2/401) of those who 
received a birth test and 0.4% (2/470) of those who only received routine EID vs. 4% (22/575) at birth returned 
a positive result. Of the 575 infants who received an HIV-PCR at birth a total of 24 infants were diagnosed as 
HIV-infected after completion of both EID tests, 92% (22) had detectable viraemia at birth signifying in utero 
infection and 2 were diagnosed at 6 weeks. At 3 months after a positive test, linkage to HIV care was 71% for 
truly infected infants diagnosed at birth and 75% for those diagnosed later; at 6 months after a positive test, 
these linkage rates were 86% (diagnosed at birth) as 3 infants linked to care in the additional 3month period and 
100% (diagnosed later) as 1 infant linked to care in the additional 3month period (Table 3). 
 
Unadjusted logistic regression analysis (Table 4) showed that only receipt of birth testing and ART coverage 
during pregnancy were associated with lower EID presentation. Maternal age, birthweight, gestation and 
population group were not associated with the outcome. From the crude analysis, it was estimated that those 
who received a birth test were 54% less likely to return for follow-up EID testing than those that did not receive 
a birth test (OR,0.46; 95%CI,0.34-0.62). The significant decrease in routine EID testing among children tested 
at birth persisted in multivariable analyses adjusting for maternal age, nadir CD4 cell count, ART use during 
pregnancy, gestational age, infant sex, maternal age, maternal population group, birthweight and infant feeding 
modality. Where possible confounding factors were included in the model which reduced the association 
between receipt of birth testing and EID presentation; the model estimated infants who received a birth test were 
40% less likely to return for EID presentation than those that did not receive a birth test (AdOR,0.60; 
95%CI,0.40-0.88), whilst those that had low ART use during pregnancy (12 weeks) were 30% less likely to 
return for EID presentation compared to those who had ≥12 weeks coverage (AdOR,0.70;95%CI, 0.46-1.06). 
Women who did not receive any ARTs during pregnancy were 57% less likely to report for EID presentation 
compared to those that had ≥12 weeks ART coverage, (AdOR,0.43; 95%CI, 0.23-0.78).  
We also assessed the effect size in different subgroup populations (Figure 1). The trend of reduced EID 
presentation after receipt of a negative test result at birth persisted across subgroup populations. Those born with 
low birthweight (n=229), preterm (n=198) or born to mothers with younger maternal age (n=259) or who did 
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not identify as black African (n=124) had the greatest influence on the association between receipt of a birth test 
and EID presentation, however, all influential subgroups had small populations (n<260) with wide confidence 
intervals often spanning 1. In order to further assess these effects, we conducted a sensitivity analyses on 826 
mother-infant dyads removing infants born with low birthweight or prematurity from the analysis. Infants born 
prematurely and with low birthweight have the highest risk of morbidity and mortality, but were also more 
likely to undergo birth testing. As these infants may have demised before routine EID testing could take place, 
they were excluded from both groups for this subgroup analysis. The negative association between birth-testing 
and EID presentation increased (AdOR, 0.54 95% CI 0.34-0.86).   
DISCUSSION 
 
These novel data are among the first to estimate routine EID test coverage of HIV-exposed infants who 
underwent birth testing in sub-Saharan Africa. There were two key findings. First, targeted birth testing 
successfully identified mothers at high risk for transmission to their infants, with diagnosis of HIV within 2 days 
of life possible for 92% of all infected infants who returned for complete EID testing. Second, neonates 
undergoing HIV testing at birth appear less likely to receive subsequent EID testing compared to infants who 
did not receive a birth test.   
 
Our data have demonstrated that while birth testing is possible and could have a higher yield of positive infants 
if implemented correctly, it is important to focus resources on all recipients of HIV results rather than only the 
infected infants. Whilst implementing targeted birth testing in a setting with high maternal HIV prevalence 
could allow for earlier identification of infected infants, it is unlikely to be suitable for all settings.  Birth testing 
could also lead to false reassurance for families whose infants return a negative result at birth and prevent 
subsequent engagement in care. It is essential that this reassurance comes after both in utero and intra-partum 
infection has been ruled out, rather than after limited and incomplete results from a single birth test (28–30).  
 
We found routine EID coverage to be higher than national estimates of 73%, with 85% of HIV-exposed infants 
who did not receive a birth test (estimated to be 75% of all deliveries), and 73% of those who received a birth 
test, returning for a follow-up EID testing (31). For HIV-infected infants, levels of linkage to care were similar 
within 3 months for infants who were diagnosed at birth or 6 weeks, but were significantly lower at 6 months 
60 
for infants diagnosed at birth. This could be explained by survival bias as infants infected in utero are at higher 
risk of rapid disease progression, and infants who were born preterm or with a low birthweight were more likely 
to receive an HIV-PCR test at birth but have 6 fold increased risk of neonatal mortality (32,33). Infected infants 
may therefore have demised before possible linkage to care could occur. 
Although the attendance at routine EID testing was higher than national estimates, the negative association 
between birth testing and EID presentation persisted through all sensitivity analysis. Unlike other studies 
looking at retention within the EID cascade, only receipt of an HIV-PCR test at birth and low ART coverage 
during pregnancy were associated with EID presentation. Predictors such as maternal age, WHO clinical stage, 
parity and preterm delivery were not associated (30,34–36). During the study period, HIV-PCR testing at birth 
was targeted to infants thought to be at high-risk of HIV transmission. Half of birth tests were attributed to 
limited ART coverage during pregnancy. Regression analysis found low ART coverage during pregnancy to be 
predictive of lower EID presentation. While the reasons behind this finding require further investigation, it is 
possible that low ART coverage could be a proxy for reduced antenatal visits and suboptimal patient care-
seeking behavior. It may suggest that risk factors associated with being at high risk of perinatal HIV 
transmission require special consideration around retention within the PMTCT/EID cascades. 
Substantial research has been conducted around the lack of retention within the EID cascade, with each step 
presenting an opportunity for loss to follow up to occur (13,37). Including a birth test in the EID algorithm adds 
additional steps into an already complicated cascade and could cause attrition in follow-up coverage. We have 
seen in other areas of the cascade that despite continuing minimal transmission risk from breastfeeding in the 
postpartum period (late postpartum infections can account for 8-25% of HIV-infections in infants) there is 
extensive loss to follow up after an initial HIV test, with very few women presenting for testing after the 
cessation of breastfeeding (38, 39,40). Receiving a negative result immediately after delivery may cause 
confusion around the need for further testing at 6 weeks, especially considering the likelihood that caregivers 
who receive a negative HIV result are significantly less likely to receive follow up counseling compared to 
those with a positive result (39). 
PMTCT services are designed to offer support to women living with HIV, and provide them with information 
for both antenatal and postnatal care, however, a report by the WHO details how counseling is often provided by 
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busy, overworked staff members, who focus only on the initial HIV test result and ART treatment (2,40,41).  It 
is possible that the association between receipt of a negative result and reduced EID presentation could be 
linked to a lack of HIV knowledge; evidence has suggested that women living with HIV in South Africa have 
inadequate knowledge of HIV transmission during the post-partum period and are unaware of EID testing 
schedules (24). The lack of focus away from the initial test result during PMTCT counselling sessions could 
limit caregivers’ knowledge around post-partum care, and continued transmission risks after labour. There is a 
clear need for further emphasis on early infant follow-up, along with ensuring accurate health records and strong 
data management to enable timely identification of infants who remain HIV-exposed and require EID testing. 
 
While the negative association between birth testing and EID presentation is of clear concern given recent 
policy changes within South Africa, the results have several limitations. First, generalizations regarding other 
settings and facility levels should be made with caution. The results reflect a single urban setting within South 
Africa. All participants were enrolled in a referral obstetric unit within a maternity service in Cape Town and 
required post discharge down referral back to the referring unit with consequent opportunity for communication 
failure and LTFU. Second, due to the retrospective nature of the research, we were unable to collect social and 
demographic variables such as HIV knowledge, employment and education of mothers that could have provided 
interesting insight into further predictors of EID presentation. We were unable to ascertain why mother/infant 
dyads were lost from care, qualitative studies focused on finding mothers lost from care and examining why 
they did not report for testing would provide greater understanding to the issues surrounding LTFU within the 
EID cascade.  We were also unable to assess the process of result return to caregivers or if and when an infected 
infant was initiated on ART, meaning that levels of LTFU could be underestimated. Finally, during the study 
period HIV-PCR testing at birth was targeted at infants thought to be at high risk of perinatal transmission. It 
would be important to repeat the study in the light of the introduction of universal birth testing to examine 
further predictors of LTFU after birth testing and reflect on the impact of targeted birth testing in this setting.  
 
In conclusion, these results show that implementation of targeted birth-testing in South Africa is extremely 
effective at identifying infected infants and has the potential to improve infant survival by increasing earlier 
access to ART for infants infected in utero who are most at risk of early death. However, there is a danger of 
reducing population coverage of routine EID services at later ages for infants testing negative at birth. PMTCT 
programmes’ counseling curricula must emphasize adherence to the new infant and child testing schedule after 
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each negative result is returned to the caregiver. Where appropriate testing schedules, counseling curriculum and 
EID services need to be revised to integrate birth testing into the EID cascade, while PMTCT programmes must 




1.  World Health Organization. Progress report on the global plan towards the elimination of new HIV 
infections among children and keeping their mothers alive. Geneva 2015. Available at: 
http://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.p df. 
Accessed 22 March 2016.  
2.  South African National Department of Health. National Consolidated Guidelines for the Prevention of 
Mother-To-Child Transmission of HIV (PMTCT) and the I of HIV in Children, Adolescents and Adults. 
2015;(April):1–128.  
3.  United Nations Joint Programme on AIDS. the Gap Report. 2014;422. Available from: 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf 
4.  GBD 2015 HIV Collaborators:, Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, et al. Estimates of 
global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global 
Burden of Disease Study 2015. Lancet HIV. 2016;0(0):1005–70.  
5.  Mayaux M-J, Burgard M, Teglas J, et al. Neonatal Characteristics in Rapidly Progressive Perinatally 
Acquired HIV-1 Disease. Ind J Sex Aqu Inf 1996;1–5.  
6.  Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected 
infants. N Engl J Med [Internet]. 2008;359(21):2233–44. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2950021&tool=pmcentrez&rendertype=abst
ract 
7.  Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental 
outcomes in infants. AIDS. 2012;26:1685–1690. http://dx.doi.org/10.1097/QAD.0b013e328355d0ce.  
8.  Prendergast AJ, Essajee S, Penazzato M. HIV and the Millennium Development Goals. Arch Dis Child 
[Internet]. 2015;100 Suppl(Suppl_1):S48–52. Available from: 
http://adc.bmj.com/content/100/Suppl_1/S48.long 
9.  Essajee S, Vojnov L, Penazzato M, et al. Reducing mortality in HIV-infected infants and achieving the 
90-90-90 target through innovative diagnosis approaches. J Int AIDS Soc. 2015;18(Suppl 6):1–5.  
63 
10. Davies MA, Pinto J. Targeting 90-90-90 - Don’t leave children and adolescents behind. J Int AIDS Soc.
2015;18(Suppl 6):1–6.
11. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-to-child HIV transmission in South Africa.






12. World Health Organization. Consolidated guidelines on the use of antiretrovirals for the treatment and
prevention of HIV infection.  2013 [Accessed 11 July 2016]; Available from:
http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html..
13. Ciaranello AL, Park J-E, Ramirez-Avila L,et al. Early infant HIV-1 diagnosis programs in resource-
limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med
[Internet]. 2011;9(1):59. Available from: http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-
7015-9-59
14. Flannery B, Thaker SN, Clippard J, et al. Interim estimates of 2013-14 seasonal influenza vaccine
effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014;63(7):137–42.
15. Bourne DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R, et al. Emergence of a peak in
early infant mortality due to HIV/AIDS in South Africa. Aids. 2009;23(1):101–6.
16. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to
HIV-infected mothers in Africa: A pooled analysis. Lancet. 2004;364(9441):1236–43.
17. Ananworanich J, Robb ML. The transient HIV remission in the Mississippi baby: Why is this good
news? J Int AIDS Soc. 2014;17:1–2.
18. Sherman G. HIV testing during the neonatal period. S Afr J HIV Med. 2015;16(1):2–4.
19. Davies M-A, May M, Bolton-Moore C, Chimbetete C, Eley B, Garone D, et al. Prognosis of Children
with HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa: A Collaborative Analysis of
Treatment Programs. Pediatr Infect Dis J. 2015;33(6):608–16.
20. Kuhn L, Kroon M. Breastfeeding and the 2015 South African guidelines for prevention of mother-to-
child transmission of HIV. S Afr J HIV Med. 2015;16(1), Art. #377, 5 pages.
   
64 
http://dx.doi.org/10.4102/sajhivmed.v16i1.377.  
21.  Lilian RR, Kalk E, Bhowan K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants 
prior to 6 weeks of age. J Clin Microbiol. 2012;50(7):2373–7.  
22.  Lilian RR, Kalk E, Technau K-G, Sherman GG. Birth diagnosis of HIV infection in infants to reduce 
infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis 
Journalnfectious Dis J [Internet]. 2013;32(10):1080–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23574775 
23.  Department of Health Republic of South Africa. National consolidated guidelines for the prevention of 
mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents 
and adults. 2014. Available from : 
http://www.inpracticeafrica.com/~/media/Guidelines/SA_NDOH_HIV_Tx.pdf  
24.  Woldesenbet SA, Jackson D, Goga AE, et al. Missed opportunities for early infant HIV diagnosis: 
results of a national study in South Africa. J Acquir Immune Defic Syndr [Internet]. 2015;68(3):e26–32. 
Available from: http://www.mendeley.com/catalog/missed-opportunities-early-infant-hiv-diagnosis-
results-national-study-south-africa-6/ 
25.  Maritz J, Hsiao N, Presier W, Myer L. Low Uptake of Routine Infant Diagnostic Testing Following 
HIV PCR Testing at Birth. In: Conference of Retroviruses and Opportunistic Infections. 2016. p. Poster 
Presentation.  
26.  Department of Health SA. Guidelines for Maternity Care in South Africa 2Department of Health, S. A. 
(2007). Guidelines for Maternity Care in South Africa 2007 : A manual for clinics, community health 
centres and district hospitals, 1–173.007 : A manual for clinics, community heal. 2015;1–173. Available 
at: https://www.health-e.org.za/wp-content/uploads/2015/11/Maternal-Care-Guidelines-2015_FINAL-
21.7.15.pdf  
27.  Kroon M. Personal Communication. University of Cape Town; 2016.  
28.  Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: New global challenges in the era 
of paediatric HIV elimination. Lancet Infect Dis [Internet]. 2016;16(6):e92–107. Available from: 
http://dx.doi.org/10.1016/S1473-3099(16)00055-4 
29.  Leshabari SC, Blystad A, de Paoli M, Moland KM. HIV and infant feeding counselling: challenges 





30. Lazarus R, Struthers H, Violari  A. Hopes, fears, knowledge and misunderstandings: responses of HIV-
positive mothers to early knowledge of the status of their baby. AIDS Care [Internet]. 2009;21(3):329–
34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19280410
31. Woldesenbet S, Goga A, Jackson D. The South African Programme To Prevent Mother-To-Child
Transmission Of Hiv (Pmtct) Evaluation I Early Infant Diagnosis Service In Primary Health Care
Facilities In South Africa: Report On Results Of A Situational Assessment 2012. 2012; Available from:
http://www.nhls.ac.za/assets/files/Situational  assessment report final_10 th Oct12.pdf
32. Slyker JA, Patterson J, Ambler G, et al. Correlates and outcomes of preterm birth, low birth weight, and
small for gestational age in HIV-exposed uninfected infants. BMC Pregnancy Childbirth [Internet].
2014;14:7. Available from: http://apps.webofknowledge.com.proxy.lib.ohio-
state.edu/full_record.do?product=UA&search_mode=CombineSearches&qid=5&SID=3DYxmnEodkBz
8Yrbc9N&page=2&doc=67
33. Shapiro RL, Lockman S. Mortality among HIV‐Exposed Infants: The First and Final Frontier. Clin
Infect Dis [Internet]. 2010;50(3):445–7. Available from:
http://cid.oxfordjournals.org/lookup/doi/10.1086/649887
34. Hassan AS, Sakwa EM, Nabwera HM, et al. Dynamics and constraints of early infant diagnosis of HIV
infection in rural Kenya. AIDS Behav. 2012;16(1):5–12.
35. Woldesenbet SA, Jackson D, Goga AE, et al. Missed Opportunities for Early Infant HIV Diagnosis :
Results of A National Study in South Africa. J Acquir Immune Defic Syndr. 2015;68(3):26–32.
36. Mnyani CN, Simango A, Murphy J,  et al. Patient factors to target for elimination of mother-to-child
transmission of HIV. Global Health [Internet]. 2014;10(1):36. Available from:
http://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-10-36
37. Sibanda EL, Weller IVD, Hakim JG, Cowan FM. The magnitude of loss to follow-up of HIV-exposed
infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic
review and meta-analysis. AIDS. 2013;27(17):2787–97.
38. Mor Z, Chemtob D, Pessach N, Nitzan-Kaluski D. Human immunodeficiency virus in new born of
infected mothers: Pregnancy, breastfeeding and prevention. Harefua. 2006;145:682–6. 70.
39. Sawe HR, Mfinanga JA, Ringo FH, et al. HIV counselling and testing practices for children seen in an
   
66 
urban emergency department of a tertiary referral hospital in Dar es Salaam, Tanzania: a retrospective 
cross-sectional study. BMJ Open [Internet]. 2016;6(2):e010298. Available from: 
http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2015-010298 
40.  Kumar A, Singh B, Kusuma YS. Counselling services in prevention of mother-to-child transmission 
(PMTCT) in Delhi, India: An assessment through a modified version of UNICEF-PPTCT tool. J 
Epidemiol Glob Health. 2015;5(1):3–13.  
41.  Rujumba J, Neema S, Tumwine JK, et al. Pregnant women’s experiences of routine counselling and 









TABLES AND FIGURES 
Table 1: Possible reasons cited for infants receiving an HIV-PCR at birth. Infants were given more than 
one possible reason for fulfilling criteria for a birth test. All reasons given for each infant were included. 
Reason For Birth Test Frequency 
(N=655) 
Percentage of Birth Tests 
(N=575) 
No Reason 37 6.4% 
ART <12weeks 221 38.4% 
Low Birthweight / Preterm 119 20.7% 
High Viral Load 85 14.8% 
Defaulted from Treatment 78 13.5% 
Unbooked 34 5.9% 
No ARVs during pregnancy 31 5.4% 
Seroconverted during Pregnancy 23 4.0% 
Maternal Infection 23 4.0% 
2nd Line Treatment 20 3.5% 
Needle stick injury 3 0.5% 
Substance Abuse 5 0.9% 
Other 10 1.7% 
Other: Respiratory distress syndrome, Meconium aspiration syndrome, voval cord paralysis, adoption, 
milksharing, AZT only, Low CD4 
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Table 2. Summary of population demographics by receipt of an HIV-PCR test at birth. (§Criteria used to 
identify high risk infants eligible for a birth HIV PCR test. #Criteria for matching HIV-exposed infants who 
received a birth test to HIV-exposed infants who did not.) 
Variable Birth Test 
 N=551 (%) 

















231 (21.0) <0.001 
Age at routine EID testing 




















229 (20.8) <0.001 
# Mode of Delivery 
C/S 260 (47.2) 260 (47.2) 520 (47.2) - 
§ Gestation (wks)
Preterm (<37) 148 (26.9) 50 (9.7) 198 (18.0) <0.001 
Infant Feeding 
Breastfeeding 438 (79.5) 460 (83.48) 898 (81.5) 0.241 









259 (23.5) <0.001 
Maternal population group 
Black African 433 (78.6) 454 (82.4) 887 (80.5) <0.001 
Gravidity 
Mean (SD) 2.5 (1.3) 2.5 (1.2) 2.5 (1.2) 0.829 
§ PMTCT Coverage
Received ART 12+weeks 












§ Default on Treatment
Recorded default 75 (13.0) - 75 (6.8) - 
§ Viral Load
VL >1000  82 (14.2) - 82 (7.4) -
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Table 3. HIV-PCR results for all HIV-exposed infants. Infants deemed to be high risk of HIV-transmission 
underwent HIV-PCR testing at birth, NHLS database was examined to determine if a confirmatory HIV-PCR or 
VL was run after the initial result. Linkage to care for truly infected infants looked for a subsequent specimen 
sent to NHLS for processing. Routine HIV PCR results reflect mother/infant dyad accessing an HIV DNA-PCR 
test after being discharged from hospital. (CT: Confirmatory Test) 




Birth HIV PCR result: 
Negative Result  
Equivocal Result  
Positive Result 
Confirmatory Test  
Possible False Positive from CT 
Linkage to HIV care w/in 3 months 

















 Birth Test 
N=401 (%) 





HIV PCR result for routine EID: 
Negative Result  
Positive Result 
Confirmatory Test 
Possible False Positive from CT 
Linkage to HIV care w/in 3 months 

























Table 4. Logistic regression analyses for predictors of EID presentation for HIV-exposed infants born at MMH in Cape Town. Variables found to be independently 
associated with the outcome of EID presentation were included in the  multivariate model  along with variables found to be significant from previous research.
Univariate Model Multivariate Model 
Risk Factors Categories Crude OR 95% CI Adjusted OR 95% CI 
Exposure to Birth Test No birth test 


























Maternal Age Age (years) 
Mature mother (≥24) 









































PMTCT Coverage Received ART 12+weeks 




























Figure 1. The adjusted odds ratio for EID presentation having received an HIV-PCR test at birth is shown  
in multiple subgroup populations. In each subgroup analysis the population was restricted to include infants 
only with the desired population. Regression analysis was then performed to estimate the association within 
each subgroup controlling for confounding variables. 




















Figure 1. Forest plot of the association between receipt of an HIV-PCR test at birth and routine EID 
presentation 
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PART D: APPENDICIES 
1. Ethical Approval Letter
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2. Site Specific Ethical Approval
Dear Lorna 
Thank you for your request to perform the research at MMH. I note that it has UCT HREC approval and is a 
retrospective record review. 
The MMH research committee would support this research being performed at MMH. 
Our medical records department is in an extreme state of chaos, so that 2013 maternal folders may not be easily 
procured. The records department is currently in the process of being sorted but this project is not nearing 
completion. Retrieval of folders for clinical or research audits has not been given priority.  It may be that you 
have funds that might allow an intern to be paid specifically to locate the required folders. 
Mother and baby are linked on clinicom. All babies who stayed with their mothers will have their records in the 
mother’s folder. All who were admitted to the nursery will have their own folder 
I am copying the request to our CEO, Janine Joemat, for her information also. 
Best wishes 
Sue Fawcus 
MA, MBBS, FRCOG, Consultant obstetrician 
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3. Table 1: Data Collection Tool
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6. Cover Letter for submission to JAIDS
Dear JAIDS Editors, 
We are pleased to submit an original article entitled “Impact of birth HIV PCR testing on uptake of follow-up 
EID services for HIV-exposed infants in Cape Town” for consideration for publication in JAIDS 
(Implementation and Operational Research). 
Despite substantial investment in the elimination of mother to child transmission of HIV (MTCT) paediatric 
HIV remain a global burden, with more than 200,000 infants identified as infected in 2014. Prompt diagnosis 
and early introduction of ART have been shown to dramatically reduce mortality in children infected with 
HIV, but identification of infected infants through virologic diagnostic testing remains a complex process.  
 The World Health Organization (WHO) currently recommends that all infants born to HIV-infected
mothers be tested for HIV by 6 weeks of age.
 There are growing concerns, that in the context of high maternal and infant prophylaxis the
sensitivity of the assay at this age is reduced.
 The current early infant diagnosis (EID) cascade already requires multiple postpartum visits, and
sees high levels of loss to follow up.
 Published studies across sub-Saharan Africa argue that delays in result return mean infected infants
often demise before the age of six weeks or become loss to follow up before successful linkage to
care can occur.
The South African National Guidelines recently recommend routine HIV PCR testing of all HIV-
exposed newborns (‘birth-testing’) to help detect in utero HIV transmission. However, birth testing 
necessitates a follow up test to detect intrapartum infections, and there are concerns around the paucity of 
data for diagnosis and treatment of infants in the neonatal period and lack of awareness on the 
impact of introducing another test into the EID cascade.  
We conducted a retrospective cohort study using routine clinical and laboratory data from a large obstetric 
hospital in Cape Town to determine the yield of birth testing in this setting and examine if receipt of a negative 
birth test result would affect the level of follow-up testing at 6-10 weeks  
 We found that 92% of infants infected with HIV were detectable at birth and levels of linkage to care
within 3 months were similar amongst those who were diagnosed at birth or those diagnosed at 6
weeks of age.
 The data also indicated that infants who underwent birth-testing may be less likely to return for a
subsequent EID test. 73% of infants returned for follow up testing after receipt of a birth test,
compared to 85% of infants who did not receive a test at birth (OR,2.17; 95%CI,1.61-2.93). Those
that did return, arrived at a significantly older age on average if they had received a birth test
previously (mean age 60vs50 days, p<0.01).
The implementation of birth testing is being more widely considered in high burden settings, it is 
important that policy makers consider the impact of introducing a birth-testing into the EID cascade. 
Successful testing to detect infants infected with HIV is an essential step towards improving life expectancy in 
this vulnerable population. It is our hope that this paper will help to broaden the discussion round birth testing 
in neonates undergoing HIV testing at birth and will contribute to the progress being made in the elimination 
of mother to child transmission. 
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Preliminary results were presented as an oral abstract at the Paediatric HIV workshop in July 2016. Our work 
reflects the first analysis of HIV-exposed infants receiving a birth test and the possible impact on follow up 
programmes from a South African birth cohort. The manuscript has not been accepted for publication 
elsewhere, and there is no overlap of the content of this paper with any prior publication. All authors have seen 
and approved the content and have contributed significantly to the work.  
Please send all correspondence to: 
Lorna Dunning, MSc 
Department of Epidemiology and Biostatistics, University of Cape Town, Anzio Road, Observatory, 7893 
ldunning@partners.org 
Thank you for your consideration. 
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7. Completed Demograohic Table for HIV-exposed infants stratified by recipt of an HIV-
PCR test at birth
Table 2: Summary population demographics by receipt of birth testing (§Criteria used to identify high risk 
infants eligible for a birth HIV PCR test. #Criteria for matching HIV-exposed infants who received a birth test 
to HIV-exposed infants who did not.) 
Variable Birth Test 
N=551 (%) 

















Age if returned for 6wk test (days): 
Mean (SD) 







































Normal  (>2500) 
Low (1500-2500) 
Very Low (1000-1500) 

















































Late Preterm (34-37) 
Moderate Preterm (32-34) 
















































































































200 – 350 





















Received ART 12+weeks 











§ Default on Treatment
No default recorded 
Recorded default 




 82 (14.2) - 82 (7.4) 
# Criteria for matching HIV-exposed infants who received a birth test to HIV-exposed infants who did not 
§Criteria used to identify high risk infants eligible for a birth HIV PCR test.
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8. Demographic Characteristics of HIV-exposed infants stratified by EID presentation.
Table 3: Description of infant characteristics eligible for an EID test at 6 week based on test
attendance (§Criteria used to identify high risk infants eligible for a birth HIV PCR test. #Criteria for
matching HIV-exposed infants who received a birth test to HIV-exposed infants who did not.)































































































































































* Data from February 2014 not included in cohort
** Data included up to August 2015
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9 . Table 4: Summary of Included Literature 
Author, 
year 
Setting Study Design Population Outcome Measured Cascade Point Key Findings 
Adebimpe, 2013 Nigeria Review HIV-exposed 
infants 
Barriers to successful 
EID programmes 
Identification of infants 
for testing 
EID programmes are hindered 
from effective EID due to health 
system constraints along with fear 
of discrimination 







mothers of accessing 
EID 
Complete cascade Mothers have fairly good 
knowledge of HIV and risks of 
transmission but face barriers of 
fear, stigma and access 




Barriers to case 
finding HIV-infected 
infants and children 
Missed HIV-infected 
infants 
Improved efforts are needed to 
find infants missed by EID testing 





initiation of EID 
Presentation for testing Presentation for EID testing 
depended upon location, access to 
care during pregnancy 




and their infants 
Interventions to 
improve rention in 
care and uptake of 
EID testing 
PMTCT/EID overlap Male partner involvement and 
mobile phone reminders may 
have important roles in retention 
in care, more evidence needed 
Ananworanich, 
2014 
USA Viewpoint HIV-infected 
infants 
Viral replication in 
infants infected with 
HIV 
Achieving remission in 
HIV-infected infants 
Amount of latent 
virus, and markers for on-going 
viral replication in infants may be 
important in achieving HIV 
remission 




and their infants 
EID presentation and 
result at 6 weeks 
PMTCT/EID overlap PMTCT interventions reduce 
transmission of HIV, infant 
feeding practices need to be 
addressed according to access to 
treatment 




Treatment outcome PMTCT cascade All people living with HIV/AIDS 
should initiate ART as early as 
possible 
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Barron, 2013 South Africa, Review HIV-infected 
pregnant women 
and their infants 
Lessons learnt in the 
elimination of MTCT 
PMTCT/EID overlap Despite excellent progress, 
challenges remain in the EMTC 
Becquet, 2012 Global Systematic review 
and meta analysis 
HIV-infected 
infants 
Survival of infants 
initiating ART 
Linkage to care and 
survival 
There remains an urgent need to 
urgency of provide ART to 
women during pregnancy to 
prevent early vertical 
transmission 
Bedelu, 2007 South Africa, 
rural 
Prospective 





for women on ART 
PMTCT Task shifting of PMTCT services 
can improve treatment outcomes. 
Barriers to treatment include 
location of facility, staff capacity 
and counselors 








attrition rates per 1000 
person-years stratified 
by age group 
Retention in care for 
HIV-infected infants 
Earlier diagnosis and treatment of 
infected infants is needed to 
reduce mortality. 






bottlenecks to  
PMTCT 
PMTCT District-level, data-driven quality 
improvement processes at a 
national scale to improve the 
performance of the PMTCT 
programme 
Bingawaho, 2013 Rwanda Programme 
evaluation for 
scale up of EID 
HIV-infected 
pregnant women 
and their infants 
Linkage to care, result 
retrun to caregivers 
EID Presentation to 
result return 
Scale up of EID programmes 
nationally have allowed 
improvements in result return but 
barriers exist to linkage to care 
Bonner, 2013 Global Systematic review HIV-infected adults Viral load to monitor 
adherence to ART 
- Viral load can be used to monitor 
adherence to ART 





under 1 year of age 
Postnatal mortality - Intrauterine and intrapartum 
infection may contribute to peak 
age of mortality of 10/11 weeks 




and their infants 
LTFU 
Reasons for LTFU Retention within EID 
cascade 
Mortality, fear of discrimination 
and disclosure issues were related 
to becoming LTFU 





linkage to care and 
Retention in care for 
infected infants 
High attrition rates from care. 
Initiation of antiretroviral therapy 
90 
cohort. retention in care increased the likelihood of 
survival 







Diagnosis of HIV using 
DBS 
DBS 
PCR will prove valuable for 
large-scale implementation of 
EID 
Chamla, 2015 Global Systematic 
Review 
HIV-exposed 
women and their 
infants 
Uptake of EID 
services, possible 
barriers to presentation 
EID presentation HIV testing during immunization 
clinic visits is acceptable and 
feasible as a possible model for 
service delivery 





Participants of the 
EID cascade 
Uptake of EID, 
linkage to care, Age of 
infants tested 
Complete EID cascade Retention in care for HIV-
exposed infants important whilst 
ensuring infected infants initiate 
treatment in a timely manner 
Cherutich, 2008 Kenya Policy Review - Identification of HIV-
infected infants, 
treatment and PMTCT 
PMTCT/EID overlap Focus is not the integration of 
PMTCT with symptomatic 
infants, testing not widely 
available 






Outcomes of infants 
within EID cascade 
Age at LTFU 
Retention in care for 
HIV-exposed infants 
LTFU major barrier in knowledge 
of HIV transmission 





Overall proportion of 
tested infants, 
prevalence 
Retention in care for 
HIV-exposed infants 
Despite oncrease in testing of 
HIV exposed infants challenges 
remain for turnaround times and 
LTFU 
Ciaranello, 2011 Resource 
limited 




LTFU within the EID 
cascade 
Complete EID cascade Even with highest reported levels 
of uptake nearly half of HIV-
infected infants may not complete 
the cascade successfully 







PMTCT Zidovudine treatment reduced 
transmission to infants 






Follow up testing rates 
for EID and age at first 
test 
EID presentation Three of four HIV-infected 
women in rural Mozambique did 
not bring their children for early 
infant HIV diagnosis 
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Coovadia, 2009 South Africa Viewpoint PMTCT 
programmes 
Call to action for 
information 
PMTCT/EID Further commitment needed to 
PMTCT programmes 




Time to failure of 
first-line ART 
Linkage to care Early time-limited ART had 
better clinical and immunological 
outcomes than deferred ART, 
Coulibaly, 2014 Burkina Faso Cross-sectional HIV-exposed 
infants 
Bottlenecks in EID, 
ART initiation 
EID cascade Limited coverage and many 
bottlenecks in PMTCT cascade 





and progress in EID 
EID cascade Decisions about when and how to 
test infants, should be made on a 
country basis for the best 
outcomes 







Diagnosis of HIV using 
DBS 
DBS PCR will prove valuable for 
large-scale implementation of 
EID 
Davies, 2015 South Africa Viewpoint HIV-infected 
infants and 
adolescents 
Achieving 90-90-90 Linkage to care challenges require multiple 
players to attain better treatment 
for infants 
Davies, 2015 South Africa Viewpoint HIV-infected 
neonates 
Challenges to neonatal 
care 
EID cascade Evidence is lacking to inform 
guidelines and programme 
development for 
Davies, 2015 Sub-Saharan 
Africa 
Systematic review HIV-infected 
infants 
ART treatment for 
infected infants 
Linkage to care There is an urgent need to address 
barriers to ART for infants 





and their infants 
Identify and explore 
barriers women face in 
accessing HIV testing 
and care for their 
infants 
LTFU from care lack of knowledge regarding EID 
and infant ART, fear of disclosure 
and lack of psychosocial support 
all limit retention in care 
Dube, 2012 Malawi Programme 
evaluation for 
scale up of EID 
HIV-infected 
pregnant women 
and their infants 
Linkage to care, result 
retrun to caregivers 
EID Presentation to 
result return 
Scale up of EID programmes 
nationally have allowed 
improvements in result return but 
barriers exist to linkage to care 
Dunning, 2015 South Africa Viewpoint HIV-infected 
infants 
Linkage to care and 
sensitivity of 
diagnositic device 
Linkage to care Sensitivty isn’t everything in 
diagnosis if logistical challenges 
removed 




and their infants 
HIV/CD4 testing and 
EID testing coverage 
PMTCT/EID coverage Optimal service delivery hard to 
maintain at decentralized 
facilities 
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Outcomes of infants 
on ART 
Retention in care on 
ART 
HAART can improve the health  
of many HIV- infected children 
with advanced disease 
Essajee, 2015 Global Commentary HIV-infected 
infants 
Outcomes of infants 
on ART 
Retention in care on 
ART 
New strategies for diagnosis 
could improve identification and 
retention in care of HIV-infected 
infants 




HIV infection and co-
morbidities 
- PMTCT/EID services should be 
integrated into wider newborn 
child healthcare 




HIV infection and co-
morbidities 
Retention in care on 
ART 
Due to high levels of LTFU new 
interventions for paediatric HIV 
case finding are required 
Francke, 2016 South Africa Modelling study HIV-exposed 
infants 
Timing of EID test Presentation to testing Cost-effective to implement a 
birth test as increase HIV-infected 
infants survival 




Barriers to EID testing EID cascade Coverage of EID remains low in 
many settings, for where it isn’t 
too few services are focused on 
retention of HIV-exposed infants 
in care 










PMTCT Virtual elimination of paediatric 
HIV infection is possible with 
intensified effort 
Gourlay, 2013 Sub-Saharan 
Africa 
Systematic review HIV-infected 
pregnant women 
Barriers to treatment PMTCT health-systems issues and 
community level factors prevent 
women accessing treatment 




Predictors of LTFU PMTCT/EID overlap Health system constraints can 
affect presentation to care for EID 
Granuch, 2009 South Africa Modelling  Adults living with 
HIV 
Transmission of HIV - Universal test and treat could 
affect transmission at the 
population level  




and their infants 
Uptake and LTFU 
within EID cascade 
PMTCT/EID overlap Lack of knowledge, inadequate 
service provision and fear of 
discrimination lead to LTFU 
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and their infants 
Uptake and LTFU 
within EID cascade 
PMTCT/EID overlap Social and economic factors, 
physiological status and 
psychological conditions lead to 
LTFU 





and their infants 
Comparison of 
recorded and reported 
information  
EID presentation Poor integration of PMTCT 
services into routine care, lack of 
clarity about health worker roles 
cause LTFU to occur 







Diagnosis of HIV using 
DBS 
POC PCR will prove valuable for 
large-scale implementation of 
EID 




Linkage to care after 
positive test result  
Linkage to care A large proportion of infected 
infants remain unlinked to 
antiretroviral therapy services and 




Linkage to care and 
treatment outcomes 
for infected infants 
Linkage to care ART initiation by three months of 
age may not adequately prevent 
disease progression 
Jani, 2014 Mozambique, 
rural 







Diagnosis of HIV using 
DBS 
POC PCR will prove valuable for 
large-scale implementation of 
EID 
Johnson, 2012 South Africa Modelling HIV-infected 
infants 
Linkage to care and 
treatment outcomes 
for infected infants 
Linkage to care ART initiation needs to occur 
earlier to have an impact on 
survival  




Retention in care, 
possible barriers  
EID presentation Socio-economic factors 
contributor to poor follow-up 







Diagnosis of HIV using 
DBS 
DBS PCR will prove valuable for 
large-scale implementation of 
EID 







coverage of HIV-PCR 
testing at birth 
EID Presentation LTFU could be increased by 
addition of an HIV-PCR test at 
birth 




potential risk factors 
for not achieving 
early diagnosis. 
EID Presentation Barriers exist causing LTFU, 
reduction in test turnaround time, 
from sample collection, to 
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laboratory, to the return of test 
results, is urgently required. 
Khamadi, 2008 Kenya Program 







EID presentation Coordinated training of health 
workers, rapid testing from a 
central laboratory and quick 
dispatch of results can minimize 
the complexities of PCR testing 




potential risk factors 
for not achieving 
early diagnosis. 
EID Presentation Barriers exist causing LTFU, 
reduction in test turnaround time, 
from sample collection, to 
laboratory, to the return of test 
results, is urgently required. 





Linkage to care Improved knowledge and 
management of neonates and 
women during pregnancy is 
required to improve outcomes 




potential risk factors 
for not achieving 
PMTCT. 
PMTCT Barriers exist causing LTFU, 
including health system and 
individual, geographic 
Lilian, 2014 South Africa Modelling HIV-infected 
infants 
Timing of infant 
testing  
Linkage to care Six weeks may no longer be the 
optimal age to diagnose perinatal 
HIV infection. Birth and 10 
weeks optimal 




Timing of detection of 
HIV infection  
Specimen Processing  76.3% of all infants with early 
HIV infections at birth and by 4 
weeks were 96% sensitive 




Timing of detection of 
HIV infection  
Specimen Processing  Six-week testing delayed 
antiretroviral therapy initiation 
beyond the time of early HIV-
related infant mortality and 
missed one-fifth of perinatally 
HIV-infected infants. Earlier 




Follow up of infants, 
outcomes, 
comorbidities 
EID cascade Careful virological monitoring of 
HIV infected infants could help 
improve outcomes  
Makau, 2015 Kenya Cross-sectional HIV-exposed 
infants 
Barriers to EID testing  EID Presentation Barriers exist causing LTFU, 
including health system and 
individual, geographic 
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EID presentation after 
a birth test 
EID Presentation Low uptake of routine EID after a 
birth test 






Survival of perinatally 
and postnatally 
infected infants 
Retention in care Those children infected 
perinatally had a much higher risk 
of dying than those infected 
through breastfeeding 




Age and acceptability 
of infant testing  
EID Presentation Testing at immunization clinics 
simpler and more acceptable.  






Barriers to EID testing  PMTCT/EID cascade Greater expansion and 
commitment to PMTCT/EID 
programmes are required to 
overcome gaps in knowledge, 
HIV resistance and further 
transmissions 






Retention in care, 
possible barriers  
EID presentation Urgent need to improve access to 
care for infected infants, majority 
eligible for ART initiation  





during pregnancy  
PMTCT Interventions required to improve 
adherence, virologic episodes 
common during pregnancy 




ART initiation PMTCT Different models of service 








EID coverage, MTCT 
rates 
EID Presentation Increase in national EID 
programme uptake and coverage, 
however linkage to ART remains 
somewhat limited, active case 
finding required  





Mortality of infants EID cascade Mortality varied by geographical 
region, and was associated with 
maternal death, and HIV infection 
Nondoki, 2015 Côte d’Ivoire Cross-sectional HIV exposed 
infants 
Maternal and Paternal 
acceptance of EID 
testing  
EID acceptance and 
testing 
Paternal consent was poor and 
result return was low. Links 
between PMTCT and PPOC 
require strengthening to improve 
 96 
children accessing ART   
Nutall, 2015 South Africa Viewpoint HIV-infected 
infants 
ART initiation Linkage to acre Safety and efficacy data on 













PMTCT/EID cascade Staff had positive attitudes, many 
challenges with HIV-disclosure 










Specificity and timing 
of testing 
Diagnosis of HIV using 
DBS 
DBS PCR will prove valuable for 
large-scale implementation of 
EID 




Overview of EID 
cascade 
PMTCT/EID cascade Little cost-effectiveness evidence 
exists about different strategies to 
deliver early infant diagnosis 
services 




Overview of EID 
cascade 
PMTCT/EID cascade Key individual, institutional, and 
systems barriers to diagnosing 
children with HIV exist 






Outcome of infected 
infants 
Linkage to care HIV progresses rapidly in 
newborns with coinfections to 
HIV 
Prendergast, 2015 Global  Viewpoint HIV-exposed 
infants 
Outcomes of HIV-
exposed infants and 
meeting global targets 
EID cascade Despite significant progress 
challenges remain for EMTCT 




Defining retention in 
care and reports on 
how to measure 
EID cascade Retention-in-care, and the ability 
to correctly measure 
it, is highly dependent on the 
challenges faced by health 
systems 
Rujumba, 2013 Uganda Qualitative – Semi 
structured 
interviews 
Pregnant women Experiences of routine 
counseling and testing 
PMTCT Strengthen post-test and follow 
up counselling for both HIV 
positive and negative women is 
required  







pretest and post-test 
counselling 
EID presentation and 
counseling  
Counselling was much more 
likely to be documented when the 
test result was positive. 
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study 




Childhood mortality EID cascade More information is needed for 
HIV-exposed uninfected infants, 
HIV-infected high levels of 
mortality 






Specificity and timing 
of testing 
Diagnosis of HIV using 
DBS 
DBS PCR will prove valuable for 
large-scale implementation of 
EID 
Sherman, 2015 South Africa Viewpoint HIV-exposed 
infants 
Timing of testing and 
linkage of HIV 
infected infants to care 
EID presentation 6 week testing is no longer the 
optimum timing for diagnosis, too 
late to impact peak age of 
mortality and too early to detect 
all infections.  





Specificity and timing 
of testing 
EID testing a single 6-week HIVDNAPCR 
test can increase identification of 
HIV-infected children 




Costing and validation 
and  
EID testing A marginal additional investment 
by government to access an 
earlier HIV diagnosis for infants 
could triple the efficacy of 
PMTCT programmes 






required to attend 
follow up visits 
EID presentation Factors associated with LTFU 
differ according to maternal HIV 
serostatus. 
Sidibe, 2016 Thailand Commentary HIV-exposed 
infants 
Elimination of Mother 
to child transmission 
EID cascade WHO certified that Thailand had 
eliminated mother-to-child 
transmission of HIV 






Diagnosis of HIV using 
DBS 
DBS PCR will prove valuable for 
large-scale implementation of 
EID 




Retention in care and 
linkage to care, infants 
receiving ART after 
HIV diagnosis 
Linkage to care Proportions of infected infants 
linked to care are extremely low. 
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Sohn, 2013 Global Review Article HIV-infected 
infants 
Retention in care, 
passing into 
adolescence 
Retention in care Challenges related to perinatally 
infected infants moving into 
adolescence, success is possible 
but there are consequences to 
lifelong ART requirements 






PMTCT Health system constraints remain 
barriers for complete access 
Varga, 2015 South Africa, 
urban 




infant testing and 
diagnosis 
EID cascade Diagnosis had both beneficial and 
detrimental psychosocial effects 





for infants accessing 
ART, delayed or 
otherwise 
ART Treatment Earlier initiation of treatment 
improves outcomes for infected 
infants 






and mortality of HIV 
- Despite scale ups in treatment, 
incident infections have not been 
prevented. Further effort required 
for 90-90-90 





number needed to test, 
infant age at testing, 
and turnaround time 
for tests 
EID presentation Diagnosis of HIV infections 
before symptom onset can 
increase survival of infected 
infants 
Willcocks, 2016 UK Qualitative HIV-infected 
mothers 
Perceived challenges 
and facilitating factors 
for mother-infant 
bonding 
EID cascade More targeted psychological 
support is required to ensure 
adequate mother infant bonding 
Woelk, 2016 Rwanda Retrospective 
cohort study 
HIV-exposed 
infants and their 
mothers 
Retention in care EID presentation 
Linkage to care 
Strategies need to be developed to 
identify, provide support and 
trace these women at risk of loss 
to follow-up 
Woldesenbet, 2015 South Africa Cross sectional HIV-exposed 
infants and their 
mothers 
Barriers to retention in 
care 
EID presentation Missed opportunities for EID 
were attributed to poor 
documentation of HIV status, 
inadequate maternal knowledge 
about mother-to-child HIV 
transmission, fear of 
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discrimination 
Yapo, 2013 Côte d’Ivoire Cross sectional HIV-exposed 
infants 
Diagnostic 
performance of assays 
EID testing Good performance using DBS for 
infant diagnosis 
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10. Table 5: Literature Search Strategy
1 HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv 2*[tiab] OR 
hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR 
human immunedeficiency virus[tiab] OR human immune-deficiency virus[tiab] OR human 
immune-deficiency virus[tiab] OR ((human immune*[tiab]) AND (deficiency virus[tiab])) OR 
acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR 
acquired immune-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] 
OR ((acquired immune*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted 
diseases, Viral"[MeSH:noexp] OR PMTCT OR mother to child transmission   
2 Child* OR infant* OR newborn OR baby OR babies OR neonatal OR birth OR postpartum 
3 Diagnosis OR Early Infant Diagnosis OR EID OR identification OR prevalence OR testing 
4 Linkage to care OR retention OR continuum of care OR attrition OR los* to follow up OR 
LTFU OR patient dropout OR LFU OR initiation OR access 
5 Barriers OR challenges OR facilitate* 
6 Pregnancy[MeSH] OR pregnan* OR OR matern* OR prevention of mother to child transmission 
OR PMTCT OR MTCT OR EID OR Early Infant Diagnosis 
7 #1 AND #2 AND #3 
8 #1 AND #4 AND #6 
9 #1 AND #2 AND #4 
10 #1 AND #5 AND #6 
